



Go Green, Go Online!
JDDonline.com

As part of the JDD green initiative, starting in 2009, the author and subject indexes will be published exclusively online. In previous years these have been printed in the December Issue, but for your convenience and for environmental consciousness, the indexes will now be available electronically.

2011 SUBJECT INDEX

Letters after article titles refer to the following: **BC** = Brief Communication; **CR** = Case Reports; **CTR** = Clinical Trial Review; **DP** = DermPearls; **NVR** = News, Views, and Reviews; **PP** = Pipeline Previews; **RR** = Resident Rounds; **RS** = Resident Spotlight

A

- Abatacept**, randomized double-blind placebo-controlled clinical trial on efficacy of abatacept costimulatory blockade in alopecia totalis/universalis, 1342
- AbobotulinumtoxinA (ABO)**
 in combined treatment for skin rejuvenation and soft tissue augmentation of aging face, 125
 comparing clinical attributes of ABO and onabotulinumtoxinA utilizing Frontalis Rating Scale and Frontalis Activity Measurement Standard, 1148
- AC-820** (nalfurafine HCl), randomized-withdrawal phase 3 study on safety and efficacy in hemodialysis and uremic pruritus (CTR), 91
- Açai berry**, aesthetic benefits of natural ingredients in skin care, s11 (September)
- Acitretin**
 assessment of national trends in treatment of psoriasis, 873
 depression associated with, 409
 in dermatology, review of literature on, 772
 low-dose, efficacy and side effects in psoriasis (CTR), 95
- Acne vulgaris**
 Acanya gel acne therapy available in pump (PP), 1479
 adapalene gel in treatment of atrophic acne scars (CTR), 96
 advantages of oral contraceptives and spironolactone for women with (DP), 941
 CME: demystifying acne algorithms, s5 (June), s24 (June), s26 (June)
 combination treatment for moderate-to-severe (CTR), 90
 comparing OTC treatment to prescription regimen (CTR), 90, 312
 dose-ranging study on safety and efficacy of IDP-107 in (CTR), 426
 efficacy and safety of azelaic acid gel 15% in post-inflammatory hyperpigmentation and, 586
 Epiduo pediatric acne study (CTR), 90, 312
 Eucerin launches campaign in Europe and Asia (PP), 1076
 evaluation of clinical improvement in acne scars and active acne in 1540-nm non-ablative fractional laser treatment, 907
 evidence-based review on fixed-combination therapy and topical retinoids in, 636
 fractional laser resurfacing for acne scarring in Fitzpatrick skin types IV–VI (DP), s6 (December)
 Gly-Sal Acne Body Spray (PP), 434
 importance of vehicles in topical therapy, s17 (June)
 inflammation in rosacea and acne, implications for patient care, 614
 introduction to demystifying acne algorithms supplement (editorial), s7 (June)
 isotretinoin does not prolong QT intervals and QT dispersion in severe acne: a surprising finding for a drug with numerous side effects, 710
 La Roche-Posay introduces new products (PP), 938
 medication choice and associated health care outcomes and costs in acne and acne-related conditions, 766
 new information regarding pathogenesis of, 582
 patient experience and management of dryness and irritation from treatment, 605
 in patients with skin of color, s13 (June)
 randomized study of dapsone gel 5% in combination with tazarotene cream 0.1% in, 783
 resveratrol-containing gel for (PP), 434
 rethinking treatment in severe patient, s8 (June)
 safety and efficacy of clindamycin phosphate 1.2%–benzoyl peroxide 3% fixed-dose combination gel for, 1382
 safety and efficacy of micronized tretinoin 0.05% gel in adolescent, 647
 self-treatment of mild-to-moderate facial acne with blue light treatment system, 596
 strategies minimizing irritation and iatrogenic post-inflammatory pigmentation in treating acne patients with skin of color (DP), s25 (December)
 study comparing Azczone plus Differin to Duac plus Differin in severe facial acne (CTR), 312
 study of new drug treatment for (CTR), 687
 ten tips for treatment in Fitzpatrick skin types IV–VI (BC), 654
 why are dermatologists still talking about acne? because so many people have it, and we are always seeking better ways to manage it (editorial), 575
- Actinic cheilitis (AC)**, treatment by photodynamic therapy with 5-aminolevulinic acid and blue light activation, 1240
- Actinic keratoses (AK)**
 comparison of cryotherapy and imiquimod for, lesion clearance, safety, and skin quality outcomes in, 1432
 effect of retinoid pretreatment on outcomes of photodynamic therapy for AK of hand and forearm, 1124
 Graceway receives FDA approval for Zyclara Cream 2.5% (PP), 1076
 imiquimod cream in combination with cryotherapy in treatment of hypertrophic AK (CTR), 426
 long-term sustained complete clearance of AK of face or balding scalp after imiquimod treatment, 165
 nonablative 1927 nm fractional resurfacing for (PP), 103
 prospective case-based assessment of sequential therapy with topical fluorouracil cream and ALA-PDT for, 372
 randomized blinded bilateral intraindividual vehicle-controlled trial of photodynamic therapy with 5-aminolevulinic acid and blue light for AK of upper extremities, 1049
 safety and efficacy comparison of blue versus red light sources for MAL-PDT in photodamaged skin, 53
 treatment with imiquimod cream followed by photodynamic therapy (CTR), 426
 trends in treatment of, 16
- Acupressure** for pruritus in atopic dermatitis (CTR), 90
- Adalimumab**
Mycobacterium fortuitum infection following adalimumab treatment for psoriasis

- and subsequent complication-free treatment with alternate TNF- α blockers (CR), 914
- and narrowband ultraviolet B light phototherapy for moderate to severe psoriasis, 366
- open-label prospective cohort pilot study on efficacy and safety of etanercept in moderate to severe plaque psoriasis in patients without adequate response to, 396
- treatment of recalcitrant generalized granuloma annulare with (CR), 1466
- Adapalene**
- adapalene gel 0.3% in atrophic acne scars (CTR), 96
- Epiduo pediatric acne study (CTR), 90, 312
- rethinking treatment of acne in severe patient, s8 (June)
- study comparing Aczone plus Differin to Duac plus Differin in severe facial acne (CTR), 312
- in topical monotherapy for acne, compared to fixed-combination therapy, 636
- Adherence to treatment**
- in once-daily therapy with sertaconazole nitrate for interdigital tinea pedis, 1135
- patient experience and management of dryness and irritation from acne treatment affecting, 605
- in topical rosacea therapy, vehicle formulations affecting, 627
- AEB071**, dose finding study assessing psoriasis area and severity index in plaque psoriasis (CTR), 92
- Aging**
- clinical evidence for activity of tetrahydropropyl ethylenediamine (THPE) as new anti-aging active cosmetic, 1102
- combined treatment for skin rejuvenation and soft-tissue augmentation of aging face, 125
- dermal fillers in skin of color population, 494
- evolution of injectable poly-L-lactic acid from correction of HIV-related facial lipatrophy to aging-related facial contour deficiencies, 1001
- guide to temporal fossa augmentation with small gel particle hyaluronic acid dermal filler in, 673
- multi-center clinical study and review of fractional ablative carbon dioxide laser resurfacing for rhytides, photoaging, scars, and striae, 352
- prospective randomized trial on effects of fluence settings in Er:YAG micropeel for facial photoaging, 179
- safety and efficacy of calcium hydroxylapatite for rejuvenation of aging hand, 47
- tower technique for injection of hyaluronic acid fillers in, 1277
- AIDS**. See HIV infection and AIDS
- AIN457**, dose-ranging study in moderate-to-severe chronic plaque-type psoriasis (CTR), 93
- Albert Einstein College of Medicine Unified Division of Dermatology**
- eruptive plexiform schwannomas in child with neurofibromatosis I (RR), 1210
- intralymphatic histiocytosis associated with orthopedic implants (RR), 1208
- program spotlight on Residency Program (RR), 1122
- sound-alike and look-alike terms in dermatology (RR), 1196
- Alefacept** for nephrogenic systemic fibrosis (CR), 922
- Alexandrite laser**
- comparison of sequential treatment with diode and alexandrite lasers versus alexandrite laser alone in hirsutism, 1255
- treating lentiginos in Asian patients with Q-switched Alexandrite laser (DP), s14 (December)
- Aloe vera**
- aesthetic benefits of natural ingredients in skin care, s11 (September)
- in atopic dermatitis and other inflammatory skin diseases, s6 (September)
- Aloesin**, aesthetic benefits of natural ingredients in skin care, s11 (September)
- Alopecia**
- approvals, long-term safety data, cancer risk, and treatment options in androgenetic alopecia in women (NVR), 98
- dutasteride versus placebo and finasteride in men with androgenetic alopecia (CTR), 936
- novel treatment of female-pattern androgenetic alopecia with injected bimatoprost 0.03% solution (CR), 795
- randomized double-blind placebo-controlled clinical trial on efficacy of abatacept costimulatory blockade in alopecia totalis/universalis, 1342
- role of inflammation and immunity in pathogenesis of androgenetic alopecia, 1404
- safety and efficacy of clobetasol propionate 0.05% emollient foam in (CTR), 1077
- safety and efficacy study of bimatoprost in women with female pattern hair loss (CTR), 936
- scalp hyperkeratosis and alopecia in children of color, 511
- START (Swiss Taxotere Alopecia Prevention Trial) (CTR), 936
- Amazingel** compared to other polyacrylamide hydrogels, 1370
- AMG 157**, safety study in healthy subjects and subjects with atopic dermatitis (CTR), 313, 687
- Aminolevulinic acid (ALA)**
- effect of retinoid pretreatment on outcomes of ALA-PDT for actinic keratosis of hand and forearm, 1124
- preliminary results of hidradenitis suppurativa treatment with ALA-PDT, 381
- prospective case-based assessment of sequential therapy with topical fluorouracil cream and ALA-PDT for actinic keratosis, 372
- randomized blinded bilateral intraindividual vehicle-controlled trial of ALA-PDT and blue light for actinic keratoses of upper extremities, 1049
- safety and efficacy comparison of blue versus red light sources for MAL-PDT in photodamaged skin, 53
- severe cutaneous reaction to ALA-PDT with blue light (CR), 1057
- treatment of actinic cheilitis by ALA-PDT and blue light activation, 1240
- Amiodarone**, Q-switched laser treatment of amiodarone pigmentation (CR), 1316
- Ammonium lactate emollient foam vehicle**, salicylic acid 6% in, for scalp psoriasis, 270
- Anakinra**
- effective for severe Muckle-Wells syndrome (PP), 214
- pilot study in severe atopic dermatitis (CTR), 313
- Anal cancer**, FDA approves Gardasil to prevent (PP), 325
- Anal fissures**, FDA approval of Rectiv for pain associated with (PP), 939
- Androgens**, decrease of insulin growth factor-1 as novel mechanism for anti-androgen effect of isotretinoin and its association with depression (BC), 793
- Anti-inflammatory agents**
- cutaneous reactions to non-steroidal anti-inflammatory drugs, 1160
- in natural ingredients, s12 (September)
- randomized study of dapsone gel 5% in combination with tazarotene cream 0.1% in acne vulgaris, 783
- Antimicrobial drugs**
- antibiotic resistance: an editorial review with recommendations, 724
- FDA approves Ceftaroline for MRSA (PP), 104
- recent advances and future directions in medical management of skin disease, 28
- rethinking treatment of acne in severe patient, s8 (June)
- Antioxidants**
- assessment of antioxidative capacity kinetics of topical antioxidants, 262
- complementary antioxidant function of caffeine and green tea polyphenols in normal human skin fibroblasts, 753
- green tea extract protects human skin fibroblasts from reactive oxygen species induced necrosis, 1096
- in natural ingredients, s11 (September)
- Apremilast**
- open label pilot study in rosacea (CTR), 313
- phase 2 open-label investigator-initiated study of safety and efficacy in recalcitrant contact or atopic dermatitis (RS), 928
- study to evaluate safety and effectiveness of oral apremilast (CC-10004) in moderate-to-severe plaque psoriasis (CTR), 1487
- Aquamid** compared to other polyacrylamide hydrogels, 1370
- Aquaphor Healing Ointment** compared to prescription barrier creams in mild-to-moderate atopic dermatitis of children, 531
- Arbutin**, aesthetic benefits of natural ingredients in skin care, s11 (September)
- Arrhythmias**, isotretinoin does not prolong QT intervals and QT dispersion in severe acne: a surprising finding for a drug with numerous side effects, 710
- L-Ascorbic acid**, evaluation of prescription strength 4% hydroquinone/10% L-ascorbic acid treatment system for photodamage in normal to oily skin, 1455
- Asian patients**
- community-based survey of skin conditions

- and concerns in South Asian Americans, 524
- treating lentigines with Q-switched Alexandrite laser in (DP), s14 (December)
- ASP015K**, study to explore efficacy and safety in moderate-to-severe psoriasis (CTR), 93, 315
- Atopic dermatitis (AD)**
- acupressure for pruritus in (CTR), 90
 - bilateral comparison study of pimecrolimus cream 1% and medical device cream in, 735
 - bilateral comparison study of pimecrolimus cream 1% and medical device emollient foam in, 666
 - comparing Cetaphil Restoraderm System versus standard skin care in infants with (CTR), 1486
 - comparison of OTC moisturizer and prescription barrier creams in mild-to-moderate AD of children, 531
 - effects of novel fluocinonide cream formulation on skin barrier function in, 171
 - efficacy, safety, and tolerability of topical nalmefene for pruritus in, 853
 - efficacy and safety of different concentrations of ZK245186 in (CTR), 313
 - efficacy of fluocinonide cream 0.1% in reducing itch in (CTR), 1486
 - natural ingredients for skin care and treatment in, s6 (September)
 - new body moisturizer increases skin hydration and improves AD symptoms in children and adults, 714
 - pediatric longitudinal evaluation on long-term safety of Protopic Ointment for (CTR), 1217
 - phase 2 open-label investigator-initiated study of safety and efficacy of apremilast in recalcitrant contact or atopic dermatitis (RS), 928
 - pilot study of Anakinra in severe AD (CTR), 313
 - recent advances in treatment of, 28
 - safety study of AMG 157 in healthy subjects and subjects with AD (CTR), 313, 687
 - sequential ascending dose study on safety and tolerability of REGN668 in (CTR), 314
 - stratum corneum abnormalities in, s9 (October)
- Autoimmune conditions**
- blisters in (RR), 491
 - bullous pemphigoid after herpes zoster vaccine administration (CR), 1328
 - effectiveness of topical tacrolimus for vitiligo in, 507
 - highlights of common autoimmune connective tissue diseases (RR), 1314
- Avotermin** in keloids (NVR), 550
- Axillary hyperhidrosis**, same-patient prospective comparison and literature review of Botox versus Dysport for (CR), 1013
- Azelaic acid**
- efficacy and safety of azelaic acid gel 15% in post-inflammatory hyperpigmentation and acne, 586
 - in topical rosacea therapy, vehicle formulations for, 627
- Azficel-T**
- FDA approval of Fibrocell Science LAVIV (PP), 939
 - in nasolabial folds and wrinkles (PP), 325, 939
- B**
- B cell lymphoma**, diffuse large, associated with biologic and other investigational agents in psoriasis (CR), 80
- Barrier creams, prescription**, compared to OTC moisturizer for mild-to-moderate atopic dermatitis in children, 531
- Barrier function of skin**. See Skin barrier function
- Basal cell carcinoma (BCC)**
- electronic brachytherapy for treatment of (CTR), 206
 - Genentech submits New Drug Application to FDA for (PP), 1340
 - study on efficacy and safety of GDC-0449 in (CTR), 206
 - ulcerated nodular nasal BCC successfully treated with imiquimod 5% cream (letter to the editor), 240
- Belimumab**, FDA approves Bellysta for lupus erythematosus (PP), 806
- Benzocaine**, methemoglobinemia risk from benzocaine topical products (PP), 684
- Benzoyl peroxide**
- Acanya gel acne therapy available in pump (PP), 1479
 - in combination treatment for moderate-to-severe acne (CTR), 90
 - Epiduo pediatric acne study (CTR), 90, 312
 - in fixed-combination therapy for acne, compared to retinoid monotherapy, 636
 - patient experience and management of dryness and irritation from acne treatment with, 605
 - rethinking treatment of acne in severe patient, s8 (June)
 - safety and efficacy of clindamycin phosphate 1.2%–benzoyl peroxide 3% fixed-dose combination gel for acne vulgaris, 1382
 - study comparing Aczone plus Differin to Duac plus Differin in severe facial acne (CTR), 312
- Betamethasone dipropionate**
- LEO Pharma launches \$0 copay program for Taclonex plaque psoriasis treatments (PP), 683
 - topical calcipotriene 0.005% and betamethasone dipropionate 0.064% maintains efficacy of etanercept after step-down dose in moderate-to-severe plaque psoriasis, 878
- Bexarotene**, study evaluating two dose levels of Targretin capsules in refractory cutaneous T-cell lymphoma (CTR), 209
- Bicillin-LA** versus placebo for chronic plaque-type psoriasis unresponsive to topical medications (CTR), 317
- Bimatoprost**
- novel treatment of female-pattern androgenetic alopecia with injected bimatoprost 0.03% solution (CR), 795
 - safety and efficacy in women with female pattern hair loss (CTR), 936
- Bio-Alcamid** compared to other polyacrylamide hydrogels, 1370
- Bioflavonoids**, randomized placebo-controlled double-blind study on efficacy of citrus bioflavonoid blend in senile purpura, 718
- Biologics**
- diffuse large B-cell lymphoma associated with biologic and other investigational agents in psoriasis (CR), 80
 - impact on disease and treatment burden of psoriasis, 189
- Biopsy diagnosis**
- clinical clues and patterns to help distinguish cutaneous metastases (NVR), 678, 930
 - comparison of diagnostic and biopsy/referral sensitivity to melanoma between dermatologists and MelaFind (RS), 1078
- Bladder cancer**
- clinical clues and patterns in biopsy diagnosis of cutaneous metastases of (NVR), 678, 930
 - review of chemopreventative effects of oral retinoids for, 1292
- Blisters**, autoimmune-mediated (RR), 491
- Blue light**
- randomized blinded bilateral intraindividual vehicle-controlled trial of photodynamic therapy with 5-aminolevulinic acid and blue light for actinic keratoses of upper extremities, 1049
 - safety and efficacy comparison of blue versus red light sources for MAL-PDT in photodamaged skin, 53
 - self-treatment of mild-to-moderate facial acne with blue light treatment system, 596
 - severe cutaneous reaction to photodynamic therapy with (CR), 1057
 - treatment of actinic cheilitis by photodynamic therapy with 5-aminolevulinic acid and blue light activation, 1240
- Botanical products**
- comparative study of safety and efficacy of 75% mulberry extract oil versus placebo as topical treatment for melasma, 1025
 - cosmeceutical and nutraceutical horizons, 24
 - evaluation of moisturizing effect of methanolic extract of five medicinal plants incorporated into cream bases using impedance and extensometry methods, 1116
 - randomized double-blind petrolatum-controlled study on efficacy of oregano extract ointment in wound healing, 1168
- Botulinum toxin**
- Allergan cell-based assay for BOTOX (PP), 938
 - in combined treatment for skin rejuvenation and soft-tissue augmentation of aging face, 125
 - comparing clinical attributes of abobotulinumtoxinA and onabotulinumtoxinA using Frontalis Rating Scale and Frontalis Activity Measurement Standard, 1148
 - cosmeceutical and nutraceutical horizons, 24
 - FDA approves Botox for chronic migraine (PP), 104
 - FDA approves Xeomin (incobotulinumtoxinA) for glabellar lines (PP), 1076
 - Frontalis Activity Measurement Standard as novel contralateral method for

- assessing botulinum neurotoxin type-A activity, 968
- in keloid management (NVR), 549
- long-term efficacy and potencies of botulinum toxin A and B (PP), 324
- rapid onset of response and patient-reported outcomes after onabotulinumtoxinA treatment of moderate-to-severe glabellar lines, 39
- same-patient prospective comparison and literature review of Botox versus Dysport for primary axillary hyperhidrosis (CR), 1013
- Brachytherapy**, electronic, for non-melanoma skin cancer treatment (CTR), 206
- Breast cancer**
- clinical clues and patterns in biopsy diagnosis of cutaneous metastases (NVR), 678, 930
- review of chemopreventative effects of oral retinoids for, 1292
- Breast reconstructive surgery**, case report of pyoderma gangrenosum following treated with immunosuppression and adjunctive xenogeneic matrix scaffolds (RR), 545
- Briakinumab** withdrawal from FDA review (PP), 435
- Brief Communications (BC)**
- assessor-blinded study of metabolic syndrome and surrogate markers of increased cardiovascular risk in children with moderate-to-severe psoriasis compared with age-matched population of children with warts, 900
- CD70 and TH17 are involved in human contact sensitivity, 1192
- community-based survey of skin conditions and concerns in South Asian Americans, 524
- decrease of insulin growth factor-1 as novel mechanism for anti-androgen effect of isotretinoin and its reported association with depression in some cases, 793
- efficacy of vorinostat in combination with interferon alpha and extracorporeal photopheresis in late stage mycosis fungoides and Sézary syndrome, 403
- ten tips for treating acne vulgaris in Fitzpatrick skin types IV–VI, 654
- Broward General Medical Center Residency Training Program**
- autoimmune-mediated blisters (for the Boards) (RR), 491
- case report on pyoderma gangrenosum following breast reconstructive surgery treated with immunosuppression and adjunctive xenogeneic matrix scaffolds (RR), 545
- program spotlight on (RR), 467
- Bupivacaine hydrochloride**, Sagent Pharmaceuticals announces FDA approval of bupivacaine hydrochloride injection (PP), 1478
- Burdock**, evaluation of moisturizing effect of methanolic extract incorporated into cream bases using impedance and extensimetry methods, 1116
- Burns**
- appearance of burn scars after fractional carbon dioxide laser treatment (CTR), 96
- chemical burn from povidone-iodine (CR), 414
- multiple facial burns with new Thermage CPT system (CR), 1320
- C**
- Caffeine**, complementary antioxidant function of caffeine and green tea polyphenols in normal human skin fibroblasts, 753
- Calcinosis cutis**, ulcerative, novel treatment for, 1042
- Calciphylaxis**, evaluation of efficacy of lanthanum carbonate in (CTR), 1342
- Calcipotriene**
- FDA approves Sorilux foam (PP), 103
- LEO Pharma launches \$0 copay program for Taclonex plaque psoriasis treatments (PP), 683
- topical calcipotriene 0.005% and betamethasone dipropionate 0.064% maintains efficacy of etanercept after step-down dose in moderate-to-severe plaque psoriasis, 878
- Calcitriol**
- multi-center open-label study on safety and efficacy of sequential treatment regimen of clobetasol propionate spray followed by calcitriol ointment in plaque psoriasis, 158
- Yin-Yang strategy in new effective repeatable sequential therapy for psoriasis, 831
- Calcium hydroxylapatite**, management of impending necrosis associated with soft tissue filler injections (CR), 1007
- Cardiovascular disease risk**
- metabolic syndrome and surrogate markers of increased cardiovascular risk in children with moderate-to-severe psoriasis compared to age-matched population with warts (BC), 900
- psoriasis drugs not linked to increased heart risks (PP), 1215
- Case Reports (CR)**
- alefacept therapy for nephrogenic systemic fibrosis, 922
- bullous pemphigoid after herpes zoster vaccine administration, 1328
- case of lichen planus following Tdap vaccination, 1067
- central serous chorioretinopathy associated with topical corticosteroids in psoriasis, 918
- chemical burn from povidone-iodine, 414
- chloracne-like drug eruption associated with sorafenib, 1331
- diffuse large B-cell lymphoma associated with biologic and other investigational agents in psoriasis, 80
- erythema multiforme-like drug reaction to sorafenib, 1462
- fatal cutaneous strongyloidiasis as side effect of mycophenolate mofetil in pemphigus foliaceus in immunocompromised patient, 418
- fixed drug eruption associated with iohexol intravenous contrast media, 802
- levamisole induced necrosis of skin and neutropenia following intranasal cocaine use: a newly recognized syndrome, 1204
- management of impending necrosis associated with soft tissue filler injections, 1007
- metallic taste as side effect of topical fluorouracil, 1201
- modified Tripier flap for lateral eyelid reconstruction, 199
- Mohs micrographic surgery for cutaneous lymphadenoma, 1324
- multiple facial burns with new Thermage CPT system, 1320
- Mycobacterium fortuitum* infection following adalimumab treatment for psoriasis and subsequent complication-free treatment with alternate TNF- α blockers, 914
- novel KRT14 mutation in epidermolysis bullosa simplex with mottled pigmentation, 926
- novel treatment of female-pattern androgenetic alopecia with injected bimatoprost 0.03% solution, 795
- pigmentary changes in patient treatment with imatinib, 1062
- post-herpetic itch resolved with gabapentin, 85
- Q-switched laser treatment of amiodarone pigmentation, 1316
- regression of internal melanoma metastases after topical application of imiquimod, 302
- rituximab dosing in refractory pemphigus vulgaris in adolescent male, 202
- same-patient prospective comparison and literature review of Botox versus Dysport for primary axillary hyperhidrosis, 1013
- severe cutaneous reaction to photodynamic therapy with blue light, 1057
- sorafenib-induced eruptive squamous cell carcinomas with keratoacanthoma-like features in hepatocellular carcinoma, 308
- tamoxifen-induced hirsutism, 799
- tattoo sites and psoriasis, 1199
- treatment of peristomal pyoderma gangrenosum with topical crushed dapson, 1059
- treatment of recalcitrant generalized granuloma annulare with adalimumab, 1466
- vesiculobullous variant of adult T-cell leukemia/lymphoma in a Caribbean émigré, 1469
- CC-10004** for prurigo nodularis (CTR), 91
- CD70** and TH17 involvement in human contact sensitivity (BC), 1192
- CD07805/47 topical gel**, phase 3 efficacy and study in facial erythema associated with rosacea (CTR), 1216
- Ceramide**
- bilateral comparison study of pimecrolimus cream 1% and ceramide-hyaluronic acid emollient foam in atopic dermatitis, 666
- ceramide-containing barrier repair cream compared to OTC moisturizer for mild-to-moderate atopic dermatitis in children, 531
- Cetaphil Restoraderm System** compared to standard skin care in infants with atopic dermatitis (CTR), 1486
- Chamomile** in atopic dermatitis and other inflammatory skin diseases, s6 (September)
- Cheilitis, actinic**, treatment by photodynamic

- therapy with 5-aminolevulinic acid and blue light activation, 1240
- Chemical burn** from povidone-iodine (CR), 414
- Chemical peels**
- in combined treatment for skin rejuvenation and soft tissue augmentation of aging face, 125
 - comparison of 1% tretinoin peeling versus 70% glycolic acid peeling in female patients with melasma, 1439
- Chemoprevention**, review of chemopreventative effects of oral retinoids for internal neoplasms, 1292
- Chemotherapy**, START (Swiss Taxotere Alopecia Prevention Trial) (CTR), 936
- Children**. See Pediatric dermatology
- Chitosan**, treatment efficacy of triple bandage compression and chitosan gel in venous leg ulcers, 75
- Chloracne-like drug eruption** associated with sorafenib (CR), 1331
- Chorioretinopathy**, central serous, associated with topical corticosteroids in psoriasis (CR), 918
- Citrus bioflavonoid blend**, randomized placebo-controlled double-blind study on efficacy in senile purpura, 718
- Cleansing product** in novel rosacea treatment system, investigator-blind randomized parallel-group study on, 1179
- Clindamycin**
- Acanya gel acne therapy available in pump (PP), 1479
 - in combination treatment for moderate-to-severe acne (CTR), 90
 - in fixed-combination therapy for acne, compared to retinoid monotherapy, 636
 - patient experience and management of dryness and irritation from acne treatment with, 605
 - safety and efficacy of clindamycin phosphate 1.2%–benzoyl peroxide 3% fixed-dose combination gel for acne vulgaris, 1382
 - study comparing Aczone plus Differin to Duac plus Differin in severe facial acne (CTR), 312
- Clinical Trial Reviews (CTR)**
- acupressure for pruritus in atopic dermatitis, 90
 - adapalene gel in treatment of atrophic acne scars, 96
 - Bicillin-LA versus placebo for chronic plaque-type psoriasis unresponsive to topical medications, 317
 - burn scar appearance after fractional carbon dioxide laser treatment, 96
 - CC-10004 for prurigo nodularis, 91
 - clinical trial of Dermacorder for detecting malignant skin lesions, 317
 - combination treatment for moderate-to-severe acne, 90
 - comparing Aczone plus Differin to Duac plus Differin in severe facial acne, 312
 - comparing Cetaphil Restoraderm System versus standard skin care in infants, 1486
 - comparing OTC acne treatment to prescription regimen, 90, 312
 - comparison of elective lymph node treatment versus clinical observation in absence of palpable lymph nodes in high risk squamous cell carcinoma, 207
 - comparison of retinol 1.0% and tretinoin 0.02% in moderate-to-severe photodamage and wrinkles, 1217
 - CP-690-550 ointment for chronic plaque psoriasis, 316
 - dapsone gel 5% for dermatitis herpetiformis, 314
 - dasatinib in locally advanced or metastatic mucosal melanoma, acral melanoma, or solar melanoma that cannot be removed by surgery, 208
 - dasatinib in unresectable or metastatic squamous cell skin cancer or RAI stage 0-1 chronic lymphocytic leukemia, 207
 - dose finding study of AEB071 assessing psoriasis area and severity index in plaque psoriasis, 92
 - dose-ranging study of AIN457 in moderate-to-severe chronic plaque-type psoriasis, 93
 - dose-ranging study on safety and efficacy of IDP-107 in acne vulgaris, 426
 - dutasteride versus placebo and finasteride in men with androgenetic alopecia, 936
 - effects of pulsed-dyed laser on scar formation, 96
 - efficacy and safety of different concentrations of ZK245186 in atopic dermatitis, 313
 - efficacy and side effects of low-dose acitretin in psoriasis, 95
 - efficacy of fluocinonide cream 0.1% in reducing itch in atopic dermatitis, 1486
 - electronic brachytherapy for non-melanoma skin cancer treatment, 206
 - Epiduo pediatric acne study, 90, 312
 - evaluation of efficacy of lanthanum carbonate in calciphylaxis, 1342
 - gemcitabine and pemetrexed disodium in advanced mycosis fungoides or Sézary syndrome, 210
 - imatinib in mucosal or acral/lentiginous melanoma, 208
 - imiquimod cream in combination with cryotherapy in treatment of hypertrophic actinic keratosis, 426
 - in vivo confocal microscopy of cutaneous neoplasms and normal skin, 318
 - lenalidomide in AIDS-related Kaposi sarcoma, 210
 - lenalidomide in relapsed mycosis fungoides/Sézary syndrome, 209
 - liposomal daunorubicin in HIV-related Kaposi's sarcoma, 212
 - long-term study to evaluate safety and tolerability of CP-690,550 in moderate-to-severe chronic plaque psoriasis, 94
 - melanoma detection by oblique-incidence optical spectroscopy, 318
 - one-year study on efficacy and safety of CP-690,550 for moderate-to-severe chronic plaque psoriasis, 688
 - open label pilot study of Apremilast in rosacea, 313
 - pediatric longitudinal evaluation on long-term safety of Protopic Ointment for atopic dermatitis, 1217
 - phase 3 efficacy and study of CD07805/47 topical gel in facial erythema associated with rosacea, 1216
 - phase 2 trial of erlotinib prior to surgery or radiation in squamous cell cancer of skin, 207
 - pilot study of Anakinra in severe atopic dermatitis, 313
 - PTC299 in HIV-related Kaposi sarcoma, 211
 - randomized double-blind placebo-controlled clinical trial on efficacy of abatacept costimulatory blockade in alopecia totalis/universalis, 1342
 - randomized double-blind placebo-controlled multi-center trial of zinc for herpes simplex labialis, 1343
 - randomized study of PH-10 for psoriasis, 315
 - randomized trial of intravenous immunoglobulin with or without cyclophosphamide in pemphigus, 1077
 - randomized-withdrawal phase 3 study on safety and efficacy of nalfurafine HCl (AC-820) in hemodialysis and uremic pruritus, 91
 - safety and efficacy of bimatoprost in women with female pattern hair loss, 936
 - safety and efficacy of clobetasol propionate 0.05% emollient foam in alopecia, 1077
 - safety and efficacy of LEO 80185 topical suspension in adolescents with scalp psoriasis, 95
 - safety and efficacy of secukinumab compared to etanercept in moderate-to-severe chronic plaque-type psoriasis, 1216
 - safety study of AMG 157 in healthy subjects and subjects with atopic dermatitis, 313, 687
 - sequential ascending dose study on safety and tolerability of REGN668 in atopic dermatitis, 314
 - sorafenib and temsirolimus in metastatic, recurrent, or unresectable melanoma, 207
 - spectral diagnosis of cutaneous malignancy, 318
 - START (Swiss Taxotere Alopecia Prevention Trial), 936
 - study evaluating two dose levels of Targretin capsules in refractory cutaneous T-cell lymphoma, 209
 - study of clinical activity, safety, and tolerability of SRT2104 in moderate-to-severe plaque-type psoriasis, 92, 314
 - study of human monoclonal antibody (zanolimumab) to treat mycosis fungoides and Sézary syndrome, 1077
 - study of LY2439821 in moderate-to-severe psoriasis, 94
 - study of new drug treatment for acne, 687
 - study of total skin electron beam therapy in stage IB-IIIa mycosis fungoides, 209
 - study of ultrasonography with elastography in skin neoplasms, 319
 - study on efficacy and safety of GDC-0449 in operable basal cell carcinoma, 206
 - study to assess VB-201 in psoriasis, 93, 316
 - study to evaluate safety and effectiveness of oral Apremilast (CC-10004) in moderate-to-severe plaque psoriasis, 1487
 - study to explore efficacy and safety of ASP015K in moderate-to-severe

- psoriasis, 93, 315
- T cell repertoire analysis of immune mediated skin diseases, 936
- topical imiquimod with Nd:YAG laser to tattoo removal, 1342
- treatment of actinic keratoses of face with imiquimod cream followed by photodynamic therapy, 426
- treatment of notalgia paresthetica with Xeomin, 91
- treatment of surgical scars using pulsed dye laser, 96, 1216
- use of etanercept as sole treatment for grade I acute graft versus host disease, 1487
- Clobetasol propionate**
- multi-center open-label study on safety and efficacy of sequential treatment regimen of clobetasol propionate spray followed by calcitriol ointment in plaque psoriasis, 158
 - open-label study on treatment of mild-to-moderate chronic hand dermatitis with 0.05% emulsion formulation foam, 1398
 - randomized controlled trial on 0.05% spray for moderate-to-severe plaque psoriasis of scalp, 885
 - safety and efficacy of 0.05% emollient foam in alopecia (CTR), 1077
 - Yin-Yang strategy in new effective repeatable sequential therapy for psoriasis, 831
- Cocaine**, levamisole induced necrosis of skin and neutropenia following intranasal cocaine use: a newly recognized syndrome (CR), 1204
- Coffeeberry**
- aesthetic benefits of natural ingredients in skin care, s12 (September)
 - Stiefel/GSK introduces Illuminence Brightening Complex (PP), 938
- Colchicine**
- in keloid management (NVR), 549
 - treatment of chronic urticaria with, 1423
- Collagen topical gel**, Cardium Therapeutics announces FDA 510(k) clearance for Excellagen (PP), 1478
- Colorectal cancer**, clinical clues and patterns in biopsy diagnosis of cutaneous metastases (NVR), 678, 930
- Complement activation** by *Mycobacterium leprae*, 274
- Complexion blending**, safety and efficacy cosmetic laser treatments in skin of color, 36
- Compression bandage** and chitosan gel in treatment of venous leg ulcers, 75
- Confocal microscopy**
- of cutaneous neoplasms and normal skin (CTR), 318
 - pilot study using reflectance confocal microscopy in assessment of novel formulation for melasma, 1260
- Contact dermatitis**
- CD70 and Th17 in (BC), 1192
 - phase 2 open-label investigator-initiated study of safety and efficacy of apremilast in recalcitrant contact or atopic dermatitis (RS), 928
- Continuing medical education**
- demythifying acne algorithms, s5 (June), s24 (June), s26 (June)
 - identifying natural ingredients and their use in skin care, s4 (September), s21 (September), s22 (September)
- Contraceptives, oral**, advantages of oral contraceptives and spironolactone for women with acne (DP), 941
- Contrast media**
- alefacept therapy for nephrogenic systemic fibrosis associated with (CR), 922
 - fixed drug eruption associated with iohexol intravenous contrast media (CR), 802
- Copper** and zinc in natural therapies for hyperpigmentation, s18 (September)
- Corrugator supercillii muscle**, terminal nerve ablation using novel thread technique for treatment of hyperdynamic vertical glabellar furrows, 762
- Corticosteroids**
- central serous chorioretinopathy associated with topical corticosteroids in psoriasis (CR), 918
 - FDA approval of Rituxan with corticosteroids for severe vasculitis (PP), 683
 - multi-center open-label study on safety and efficacy of sequential treatment regimen of clobetasol propionate spray followed by calcitriol ointment in plaque psoriasis, 158
 - reported adverse effects of isotretinoin and (RR), 287
 - Yin-Yang strategy in new effective repeatable sequential therapy for psoriasis, 831
- Cosmetic dermatology**
- Alma Lasers introduces iPixel fractional ablative technology (PP), 805
 - assessment of antioxidative capacity kinetics of cosmetic formulation, 262
 - clinical evidence for activity of tetrahydroxypropyl ethylenediamine (THPE) as new anti-aging active cosmetic, 1102
 - combined treatment for skin rejuvenation and soft-tissue augmentation of aging face, 125
 - corrugator supercillii muscle terminal nerve ablation using novel thread technique for treatment of hyperdynamic vertical glabellar furrows, 762
 - cosmeceutical and nutraceutical horizons, 24
 - cosmetic treatments on skin of color, a unique challenge (editorial), s4 (December)
 - dermal fillers in skin of color population, 494
 - efficacy and tolerability of new monophasic double-crosslinked hyaluronic acid filler for deep lines and wrinkles, 134
 - guide to temporal fossa augmentation with small gel particle hyaluronic acid dermal filler, 673
 - open-label pilot study on effectiveness and safety of hyaluronic acid in lip augmentation, 145
 - prospective randomized trial on effects of fluence settings in Er:YAG micropeel for facial photoaging, 179
 - rapid onset of response and patient-reported outcomes after onabotulinumtoxinA treatment of moderate-to-severe glabellar lines, 39
 - Safe Cosmetics Act of 2011 (PP), 1215
 - safety and efficacy of cosmetic laser treatments for skin of color, 35
- Cost considerations**
- increased prevalence of psychiatric disorders and health care-associated costs in moderate-to-severe psoriasis, 843
 - medication choice and associated health care outcomes and costs in acne and acne-related conditions, 766
- CP-690,550**
- for chronic plaque psoriasis (CTR), 316
 - long-term study to evaluate safety and tolerability in moderate-to-severe chronic plaque psoriasis (CTR), 94
 - one-year study on efficacy and safety for moderate-to-severe chronic plaque psoriasis (CTR), 688
- Cryotherapy**
- compared to imiquimod for actinic keratoses, lesion clearance, safety, and skin quality outcomes in, 1432
 - comparison of dimethyl ether and propane to liquid nitrogen in cryosurgical treatment of warts, case report and review of literature on, 1174
 - imiquimod cream in combination with, in treatment of hypertrophic actinic keratosis (CTR), 426
- Cutis laxa**, acquired, cutaneous hypersensitivity during selective serotonin reuptake inhibitor therapy resulting in (RR), 215
- Cyclophosphamide**, randomized trial of intravenous immunoglobulin with or without cyclophosphamide in pemphigus (CTR), 1077
- D**
- Dapsone**
- in dermatitis herpetiformis (CTR), 314
 - randomized study of dapsone gel 5% in combination with tazarotene cream 0.1% in acne vulgaris, 783
 - study comparing Aczone plus Differin to Duac plus Differin in severe facial acne (CTR), 312
 - treatment of peristomal pyoderma gangrenosum with topical crushed dapsone (CR), 1059
- Dasatinib**
- in locally advanced or metastatic mucosal melanoma, acral melanoma, or solar melanoma that cannot be removed by surgery (CTR), 208
 - in unresectable or metastatic squamous cell skin cancer or RAI stage 0-1 chronic lymphocytic leukemia (CTR), 207
- Daunorubicin**, liposomal, in HIV-related Kaposi's sarcoma (CTR), 212
- Depression**
- associated with acitretin, 409
 - decrease of insulin growth factor-1 as novel mechanism for anti-androgen effect of isotretinoin and its association with depression (BC), 793
- Dermabrasion**, treatment of vitiligo with melanocyte-keratinocyte cell suspension versus dermabrasion only in pilot study with 12-month follow-up, 1032
- Dermacorder**, clinical trial on detecting malignant skin lesions with (CTR), 317
- Dermal fillers**
- clinical pearls for dermal filler enhancement in patients with skin of color (DP), s23 (December)
 - in combined treatment for skin rejuvenation and soft tissue augmentation of aging face, 125

- commentary on rheological evaluation of the physical properties of hyaluronic acid dermal fillers (letter to the editor), 964
- cosmeceutical and nutraceutical horizons, 24
- efficacy and tolerability of new monophasic double-crosslinked hyaluronic acid filler for deep lines and wrinkles, 134
- guide to temporal fossa augmentation with small gel particle hyaluronic acid dermal filler, 673
- open-label pilot study on effectiveness and safety of hyaluronic acid in lip augmentation, 145
- rheological evaluation of physical properties of hyaluronic acid dermal fillers, 974
- safety and efficacy of calcium hydroxylapatite for rejuvenation of aging hand, 47
- in skin of color population, 494
- tower technique for injection of hyaluronic acid fillers in, 1277
- DermaPACE device** for diabetic foot ulcers (PP), 325
- Dermatitis**
- atopic. *See* Atopic dermatitis (AD)
- CD70 and Th17 in contact dermatitis (BC), 1192
- dapsone gel 5% for dermatitis herpetiformis (CTR), 314
- managing epidermal barrier function in treatment of dermatoses, s13 (October)
- open-label study of safety and efficacy of sertaconazole nitrate in seborrheic dermatitis, 895
- open-label study on treatment of mild-to-moderate chronic hand dermatitis with clobetasol propionate 0.05% emulsion formulation foam, 1398
- phase 2 open-label investigator-initiated study of safety and efficacy of apremilast in recalcitrant contact or atopic dermatitis (RS), 928
- Dermatofibrosarcoma protuberans**, malignancy arising with cutaneous tattoo, 837
- Dermatology education.** *See* Resident Rounds (RR); Training
- Dermatomyositis, fulminant**, with flagellate erythema (RR), 902
- Dermoscopy, multispectral digital**, computer-based analysis in, 21
- DermPearls (DP)**
- advantages of oral contraceptives and spironolactone for women with acne, 941
- best practices and evidence-based use of 800 nm diode laser for pseudofolliculitis barbae in skin of color, s20 (December)
- clinical pearls for dermal filler enhancement in patients with skin of color, s23 (December)
- diode 810 nm laser as safe, effective modality to meet a growing population need, s8 (December)
- fractional laser resurfacing for acne scarring in Fitzpatrick skin types IV–VI, s6 (December)
- importance of before and after photographs to practice, 940
- laser hair removal in ethnic skin, principles and practical aspects of, s17 (December)
- laser hair removal pearls in skin of color, s12 (December)
- novel 0.65 millisecond pulsed 1064 nm laser to treat skin of color without skin cooling or anesthetics, s10 (December)
- strategies minimizing irritation and iatrogenic post-inflammatory pigmentation in treating acne patients with skin of color, s25 (December)
- treating lentigines in Asian patients with Q-switched Alexandrite laser, s14 (December)
- Devices and equipment**
- Alma Lasers introduces iPixel fractional ablative technology (PP), 805
- clinical trial of Dermacorder for detecting malignant skin lesions (CTR), 317
- CoreRx Pharmaceuticals introduces Xcelodose micro-dosing system (PP), 1478
- dermaPACE device for diabetic foot ulcers (PP), 325
- Ellman International introduces Pellevé Wrinkle Reduction System to European market (PP), 938
- FDA clearance of EndyMed Fractional Skin Resurfacing Applicator (PP), 435
- FDA gives provisional approval to MelaFind device (PP), 1340
- FDA grants marketing clearance for HairMax Dual 12 home-use laser phototherapy device (PP), 1341
- FDA panel votes in favor of MelaFind skin cancer detection device (PP), 213
- multiple facial burns with new Thermage CPT system (CR), 1320
- self-treatment of mild-to-moderate facial acne with blue light treatment system, 596
- spectral diagnosis probe in cutaneous malignancy detection (CTR), 318
- Syneron devices at 22nd world Congress of Dermatology (PP), 805
- Dexpantenol** in atopic dermatitis and other inflammatory skin diseases, s6 (September)
- Diabetes mellitus**, dermaPACE device for diabetic foot ulcers (PP), 325
- Diffuse large B-cell lymphoma** associated with biologic and other investigational agents in psoriasis (CR), 80
- Dimethyl ether and propane** compared to liquid nitrogen in cryosurgical treatment of warts, case report and review of literature on, 1174
- Diode laser**
- best practices and evidence-based use of 800 nm diode laser for pseudofolliculitis barbae in skin of color (DP), s20 (December)
- comparison of high-fluence single-pass diode laser to low-fluence multiple-pass diode laser for hair reduction with 18 months of follow up, 62
- comparison of sequential treatment with diode and alexandrite lasers versus alexandrite laser alone in hirsutism, 1255
- diode 810 nm laser as safe, effective modality to meet a growing population need (DP), s8 (December)
- Discoid lupus**, is chronic cutaneous discoid lupus protective against severe renal disease in systemic lupus erythematosus?, 1413
- Doxycycline**
- compared to minocycline for management of acne (letter to the editor), 965, 966
- rethinking treatment of acne in severe patient, s8 (June)
- self-reported treatment impressions and satisfaction of papulopustular rosacea patients treated with doxycycline USP 40 mg capsules, 1376
- Drug calendar, electronic**, in cutaneous drug eruptions, 1430
- Drug reactions/toxicity**
- case of lichen planus following Tdap vaccination (CR), 1067
- causes and clinical courses of drug-induced urticaria, 1019
- central serous chorioretinopathy associated with topical corticosteroids in psoriasis (CR), 918
- chemical burn from povidone-iodine (CR), 414
- chloracne-like drug eruption associated with sorafenib (CR), 1331
- clinical trial safety and mortality analysis of etanercept across approved indications, 289
- creation of electronic drug calendar in drug hypersensitivity, 1430
- cutaneous hypersensitivity during selective serotonin reuptake inhibitor therapy resulting in acquired cutis laxa (RR), 215
- cutaneous reactions to non-steroidal anti-inflammatory drugs, 1160
- erythema multiforme-like drug reaction to sorafenib (CR), 1462
- fixed drug eruption associated with iohexol intravenous contrast media (CR), 802
- iododerma following radioactive iodine ablation of thyroid for Graves disease (RR), 1070
- isotretinoin does not prolong QT intervals and QT dispersion in severe acne: a surprising finding for a drug with numerous side effects, 710
- levamisole induced necrosis of skin and neutropenia following intranasal cocaine use: a newly recognized syndrome (CR), 1204
- levamisole-induced retiform purpura (RR), 217
- metallic taste as side effect of topical fluorouracil (CR), 1201
- methemoglobinemia risk from benzocaine topical products (PP), 684
- pigmentary changes in patient treatment with imatinib (CR), 1062
- Q-switched laser treatment of amiodarone pigmentation (CR), 1316
- reported adverse effects of isotretinoin and systemic corticosteroids (RR), 287
- short-term and low-dose oral fluconazole treatment can cause Stevens-Johnson syndrome in HIV-negative patients (letter to the editor), 1360
- sorafenib-induced eruptive squamous cell carcinomas with keratoacanthoma-like features (CR), 308
- tamoxifen-induced hirsutism (CR), 799
- Drug resistance**
- antibiotic resistance: an editorial review with recommendations, 724
- FDA approves Ceftriaxone for MRSA (PP), 104
- recent advances and future directions in

medical management of skin disease, 28

Dutasteride

in female androgenetic alopecia (NVR), 98
versus placebo and finasteride in men with androgenetic alopecia (CTR), 936

Dyschromia, laser treatment with novel 607 nm pulsed-dye laser, 388

E**Eastern Virginia Medical School Residency Program**

program spotlight on (RR), 344
ticks of dermatologic significance (RR), 365
viral-associated trichodysplasia of immunosuppression in renal transplant patient (RR), 422

Editorials

cancer: this war is personal, 237
commentary on rheological evaluation of the physical properties of hyaluronic acid dermal fillers, 964
cosmetic treatments on skin of color, a unique challenge, s4 (December)
defining the future of dermatology, 15
doxycycline versus minocycline for management of acne, 965, 966
introduction to demystifying acne algorithms supplement, s7 (June)
introduction to DermPearls supplement, s4 (December)
JDD goes international, 581
JDD receives impact factor ranking of 1.954, 1234
lessons from an exemplary physician in private setting, 238
new face of fillers: why evidence and experience both count, 964
role of stratum corneum in healthy and diseased skin, s4 (October)
short-term and low-dose oral fluconazole treatment can cause Stevens-Johnson syndrome in HIV-negative patients, 1360
skin of color: progress made, challenges remain, 459
ulcerated nodular nasal basal cell carcinoma successfully treated with imiquimod 5% cream, 240
why are dermatologists still talking about acne? because so many people have it, and we are always seeking better ways to manage it, 575

Efalizumab, diffuse large B-cell lymphoma associated with biologic and other investigational agents in psoriasis (CR), 80

Elastography, ultrasonic, in skin neoplasms (CTR), 319

Electrocardiography, isotretinoin does not prolong QT intervals and QT dispersion in severe acne: a surprising finding for a drug with numerous side effects, 710

Electronic medical records, creation of electronic drug calendar in drug hypersensitivity, 1430

Eletone cream, bilateral comparison study of pimecrolimus cream 1% and medical device cream in atopic dermatitis, 735

Epidemolysis bullosa simplex with mottled pigmentation, novel KRT14 mutation in (CR), 926

Erbium:YAG micropeel treatment, prospective randomized trial on effects of fluence

settings for facial photoaging, 179

Erlotinib, phase 2 trial in squamous cell cancer prior to surgery or radiation (CTR), 207

Erythema

erythema multiforme-like drug reaction to sorafenib (CR), 1462
fulminant dermatomyositis with flagellate erythema (RR), 902
phase 3 efficacy and study of CD07805/47 topical gel in facial erythema associated with rosacea (CTR), 1216
thalidomide and complement activation in erythema nodosum leprosum, 274

Erythrasma, case of trichomycosis axillaris and (RR), 1472

Erythromycin in fixed-combination therapy for acne, compared to retinoid monotherapy, 636

Estrogen, advantages of oral contraceptives and spironolactone for women with acne (DP), 941

Etanercept

clinical trial safety and mortality analysis across approved indications, 289
open-label prospective cohort pilot study on efficacy and safety in moderate to severe plaque psoriasis in patients without adequate response to adalimumab, 396
retrospective study of racial and ethnic variations in psoriasis treatment with, 866
safety and efficacy of secukinumab compared to etanercept in moderate-to-severe chronic plaque-type psoriasis (CTR), 1216
as sole treatment for grade I acute graft versus host disease (CTR), 1487
topical calcipotriene 0.005% and betamethasone dipropionate 0.064% maintains efficacy of etanercept after step-down dose in moderate-to-severe plaque psoriasis, 878

Ethnicity. See Race/ethnicity

Etretinate, depression associated with, 409

Extensimetry, evaluation of moisturizing effect of methanolic extract of five medicinal plants incorporated into cream bases using, 1116

Eyelid, modified Tripiier flap for lateral eyelid reconstruction (CR), 199

F

Facial lipoatrophy, evolution of injectable poly-L-lactic acid from correction of HIV-related facial lipoatrophy to aging-related facial contour deficiencies, 1001

Facial rejuvenation

clinical evidence for activity of tetrahydroxypropyl ethylenediamine (THPE) as new anti-aging active cosmetic, 1102

combined treatment for skin rejuvenation and soft-tissue augmentation of aging face, 125

Ellman International introduces Pellevé Wrinkle Reduction System to European market (PP), 938

evolution of injectable poly-L-lactic acid from correction of HIV-related facial lipoatrophy to aging-related facial contour deficiencies, 1001

FDA approval for Syneron LED-based skin

rejuvenation system (PP), 435

guide to temporal fossa augmentation with small gel particle hyaluronic acid dermal filler, 673

histological and immunohistochemical evaluation of intense pulsed light photorejuvenation, 1246

multi-center clinical study and review of fractional ablative carbon dioxide laser resurfacing for rhytides, photoaging, scars, and striae, 352

safety and efficacy of cosmetic laser treatments for skin of color, 36

tower technique for injection of hyaluronic acid fillers in, 1277

Feverfew

aesthetic benefits of natural ingredients in skin care, s12 (September)
in atopic dermatitis and other inflammatory skin diseases, s6 (September)

Fibroblasts

complementary antioxidant function of caffeine and green tea polyphenols in normal human skin fibroblasts, 753
green tea extract protects human skin fibroblasts from reactive oxygen species induced necrosis, 1096

Fibrosis, nephrogenic systemic

alefacept therapy for (CR), 922
case report and literature review (RR), 622

Finasteride

dutasteride versus placebo and finasteride in men with androgenetic alopecia (CTR), 936
in female androgenetic alopecia (NVR), 98

Fitzpatrick skin types

acne in patients with skin of color, s13 (June)
fractional laser resurfacing for acne scarring in Fitzpatrick skin types IV–VI (DP), s6 (December)
safety and efficacy of cosmetic laser treatments for skin of color, 35
ten tips for acne vulgaris treatment in Fitzpatrick skin types IV–VI (BC), 654

Fixed drug eruption associated with iohexol intravenous contrast media (CR), 802

Fluconazole, short-term and low-dose oral fluconazole treatment can cause Stevens-Johnson syndrome in HIV-negative patients (letter to the editor), 1360

Fluocinonide

effects of novel formulation on skin barrier function in atopic dermatitis, 171
efficacy of fluocinonide cream 0.1% in reducing itch in atopic dermatitis (CTR), 1486

5-Fluorouracil

metallic taste as side effect of (CR), 1201
optimal use in keloids (NVR), 548
prospective case-based assessment of sequential therapy with topical fluorouracil cream and ALA-PDT for actinic keratosis, 372

Fluticasone propionate, injection lipolysis of abdominal subcutaneous fat yields results (PP), 103

Follistatin, hair regrowth following a Wnt- and follistatin-containing treatment, safety and efficacy in first-in-man phase 1 clinical trials, 1308

Food and Drug Administration

Abbott withdraws briakinumab from FDA

review (PP), 435

approval of Allergan cell-based assay for BOTOX (PP), 938

approval of Benlysta for lupus erythematosus (PP), 806

approval of Botox for chronic migraine (PP), 104

approval of Ceftaroline for MRSA (PP), 104

approval of Fibrocell Science LAVIV (PP), 939

approval of first generic versions of levofloxacin (PP), 1076

approval of Gardasil to prevent anal cancer (PP), 325

approval of Glenmark Generics mupirocin 2% ointment (PP), 939

approval of imiquimod 5% cream (PP), 683

approval of ipilimumab (PP), 552

approval of Natroba for head lice (PP), 434

approval of Rectiv (nitroglycerin) ointment (PP), 939

approval of Rituxan with corticosteroids for severe vasculitis (PP), 683

approval of Sorilux (calcipotriene) foam (PP), 103

approval of Sylatron to treat melanoma (PP), 684

approval of Syneron LED-based skin rejuvenation system (PP), 435

approval of Xeomin (incobotulinumtoxinA) (PP), 1076

approval of Zelboraf (vemurafenib) (PP), 1215

approval of Zyclara Cream 3.75% for external genital warts (PP), 552

ban on skin whitening products containing mercury (PP), 1215

Cardium Therapeutics announces FDA 510(k) clearance for Excellagen (PP), 1478

clearance of EndyMed Fractional Skin Resurfacing Applicator (PP), 435

clearance of PinPointe FootLaser for nail fungus (PP), 104

Cleure launches FDA-approved broad-spectrum sunscreen (PP), 1076

Fibrocell Science, Inc. and azficel-T (PP), 325

Genentech submits New Drug Application to (PP), 1340

Graceway receives FDA approval for Zyclara Cream 2.5% for actinic keratosis (PP), 1076

grants marketing clearance for HairMax Dual 12 home-use laser phototherapy device (PP), 1341

Helix Biopharma Corp. files clinical hold response on topical interferon alpha-2b (PP), 1478

New Drug Application for Yaupon's mechlorethamine hydrochloride (PP), 1478

new drug applications for vemurafenib in advanced skin cancer (PP), 805

panel votes in favor of MelaFind skin cancer detection device (PP), 213

provisional approval to MelaFind device (PP), 1340

Sagent Pharmaceuticals announces FDA approval of bupivacaine hydrochloride injection (PP), 1478

warning letter to Jaba Labs LLC (PP), 552

Foot

clinical evaluation of safety and efficacy of new topical treatment for onychomycosis, 1186

dermaPACE device for diabetic foot ulcers (PP), 325

once-daily therapy with sertaconazole nitrate for interdigital tinea pedis, 1135

randomized double-blind vehicle-controlled efficacy and safety study of naftifine 2% cream in tinea pedis, 1282

Fractionated laser therapy

for acne scarring in Fitzpatrick skin types IV–VI (DP), s6 (December)

Alma Lasers introduces iPixel fractional ablative technology (PP), 805

burn scar appearance after fractional carbon dioxide laser treatment (CTR), 96

evaluation of clinical improvement in acne scars and active acne in 1540-nm non-ablative fractional laser treatment, 907

multi-center clinical study and review of fractional ablative carbon dioxide laser resurfacing for rhytides, photoaging, scars, and striae, 352

multiplexed 1,440 and 1,320 nm fractionated laser for chronic photodamage, 1266

nonablative 1927 nm fractional resurfacing for actinic keratoses (PP), 103

Frontalis Activity Measurement Standard

comparing clinical attributes of abobotulinumtoxinA and onabotulinumtoxinA using, 1148

novel contralateral method for assessing botulinum neurotoxin type-A activity, 968

Frontalis Rating Scale

assessing botulinum neurotoxin type-A activity with, 968

comparing clinical attributes of abobotulinumtoxinA and onabotulinumtoxinA using, 1148

Fungal infections

clinical evaluation of safety and efficacy of new topical treatment for onychomycosis, 1186

double-blind randomized vehicle-controlled study on efficacy and safety of naftifine 2% cream in tinea cruris, 1142

once-daily therapy with sertaconazole nitrate for interdigital tinea pedis, 1135

randomized double-blind vehicle-controlled efficacy and safety study of naftifine 2% cream in tinea pedis, 1282

role of lasers in onychomycosis (NVR), 1074

short-term and low-dose oral fluconazole treatment can cause Stevens-Johnson syndrome in HIV-negative patients (letter to the editor), 1360

G

Gabapentin, post-herpetic itch resolved with (CR), 85

Gadolinium, alefacept therapy for nephrogenic systemic fibrosis associated with (CR), 922

Gardasil, FDA approval for prevention of anal cancer (PP), 325

GDC-0449, study on efficacy and safety in operable basal cell carcinoma (CTR), 206

Gelatin sponges in Mohs micrographic surgery defects and staged melanoma excisions, 68

Gemcitabine and pemetrexed disodium in advanced mycosis fungoides or Sézary syndrome (CTR), 210

Genetics

genes in psoriasis (NVR), 1337

recent advances and future directions in medical management of skin disease, 28

Genital warts, external, FDA approves Zyclara Cream 3.75% for (PP), 552

Glabella lines

comparing clinical attributes of abobotulinumtoxinA and onabotulinumtoxinA using Frontalis Rating Scale and Frontalis Activity Measurement Standard, 1148

corrugator supercilii muscle terminal nerve ablation using novel thread technique for treatment of hyperdynamic vertical glabella furrows, 762

FDA approval of Xeomin (incobotulinumtoxinA) for (PP), 1076

rapid onset of response and patient-reported outcomes after onabotulinumtoxinA treatment of moderate-to-severe glabella lines, 39

Glycolic acid

comparison of 1% tretinoin peeling versus 70% glycolic acid peeling in female patients with melasma, 1439

in Gly-Sal Acne Body Spray (PP), 434

Glycyrrhetic acid-containing barrier repair cream (BRC-Gly)

compared to OTC moisturizer for mild-to-moderate atopic dermatitis in children, 531

Graft versus host disease, acute grade I, use of etanercept as sole treatment for (CTR), 1487

Granuloma annulare, recalcitrant, treatment with adalimumab (CR), 1466

Graves disease, iododerma following radioactive iodine ablation of thyroid for (RR), 1070

Green tea

aesthetic benefits of natural ingredients in skin care, s12 (September)

complementary antioxidant function of caffeine and green tea polyphenols in normal human skin fibroblasts, 753

green tea extract protects human skin fibroblasts from reactive oxygen species induced necrosis, 1096

Growth factors, decrease of insulin growth factor-1 as novel mechanism for anti-androgen effect of isotretinoin and its association with depression (BC), 793

H**Hair**

advances in laser hair removal in skin of color, 1235

approvals, long-term safety data, cancer risk, and treatment options in androgenetic alopecia in women (NVR), 98

case of trichomycosis axillaris and erythrasma (RR), 1472

comparison of high-fluence single-pass diode laser to low-fluence multiple-pass diode laser for hair reduction with 18 months of follow up, 62

comparison of sequential treatment with diode and alexandrite lasers versus alexandrite laser alone in hirsutism, 1255

dutasteride versus placebo and finasteride

- in men with androgenetic alopecia (CTR), 936
- FDA grants marketing clearance for HairMax Dual 12 home-use laser phototherapy device (PP), 1341
- hair findings board review (RR), 1464
- hair regrowth following a Wnt- and follistatin-containing treatment, safety and efficacy in first-in-man phase 1 clinical trials, 1308
- laser hair removal in ethnic skin, principles and practical aspects of (DP), s17 (December)
- laser hair removal pearls in skin of color (DP), s12 (December)
- novel 0.65 millisecond pulsed 1064 nm laser to treat skin of color without skin cooling or anesthetics (DP), s10 (December)
- novel treatment of female-pattern androgenetic alopecia with injected bimatoprost 0.03% solution (CR), 795
- randomized double-blind placebo-controlled clinical trial on efficacy of abatacept costimulatory blockade in alopecia totalis/universalis, 1342
- ROGAINE introduces Unscented Topical Foam (PP), 1076
- role of inflammation and immunity in pathogenesis of androgenetic alopecia, 1404
- safety and efficacy of clobetasol propionate 0.05% emollient foam in alopecia (CTR), 1077
- safety and efficacy of laser hair removal for skin of color, 35
- safety and efficacy study of bimatoprost in women with female pattern hair loss (CTR), 936
- scalp hyperkeratosis and alopecia in children of color, 511
- START (Swiss Taxotere Alopecia Prevention Trial) (CTR), 936
- tamoxifen-induced hirsutism (CR), 799
- Hand**
- open-label study on treatment of mild-to-moderate chronic hand dermatitis with clobetasol propionate 0.05% emulsion formulation foam, 1398
- safety and efficacy of calcium hydroxylapatite for rejuvenation of aging hand, 47
- Harvard Combined Dermatology Residency Training Program**
- high-yield dermatologic signs in (RR), 197
- program spotlight on (RR), 186
- Head and neck cancer**
- Mohs micrographic surgery for cutaneous lymphadenoma (CR), 1324
- review of chemopreventative effects of oral retinoids for, 1292
- Head lice**, FDA approves Natroba for (PP), 434
- Health care costs**
- increased prevalence of psychiatric disorders and health care-associated costs in moderate-to-severe psoriasis, 843
- medication choice and associated health care outcomes and costs in acne and acne-related conditions, 766
- Health care outcomes**, medication choice and associated health care outcomes and costs in acne and acne-related conditions, 766
- Heart**
- isotretinoin does not prolong QT intervals and QT dispersion in severe acne: a surprising finding for a drug with numerous side effects, 710
- metabolic syndrome and surrogate markers of increased cardiovascular risk in children with moderate-to-severe psoriasis compared to age-matched population with warts (BC), 900
- psoriasis drugs not linked to increased heart risks (PP), 1215
- Hemodialysis**, randomized-withdrawal phase 3 study on safety and efficacy of nalfurafine HCl (AC-820) for uremic pruritus in (CTR), 91
- Hepatocellular carcinoma**
- clinical clues and patterns in biopsy diagnosis of cutaneous metastases of (NVR), 678, 930
- review of chemopreventative effects of oral retinoids for, 1292
- sorafenib-induced eruptive squamous cell carcinomas with keratoacanthoma-like features in (CR), 308
- Herbal extracts**
- evaluation of moisturizing effect of methanolic extract of five medicinal plants incorporated into cream bases using impedance and extensimetry methods, 1116
- randomized double-blind petrolatum-controlled study on efficacy of oregano extract ointment in wound healing, 1168
- Herpes simplex labialis**, randomized double-blind placebo-controlled multi-center trial of zinc for (CTR), 1343
- Herpes zoster**
- bullous pemphigoid after herpes zoster vaccine administration (CR), 1328
- herpes zoster vaccine reduces zoster risk (PP), 324
- post-herpetic itch resolved with gabapentin (CR), 85
- Hidradenitis suppurativa**, preliminary results of treatment with ALA-PDT, 381
- Hirsutism**
- comparison of sequential treatment with diode and alexandrite lasers versus alexandrite laser alone in, 1255
- safety and efficacy of laser hair removal in, 35
- tamoxifen-induced (CR), 799
- Histiocytosis**, intralymphatic, associated with orthopedic implants (RR), 1208
- Histology**, histological and immunohistochemical evaluation of intense pulsed light photorejuvenation, 1246
- HIV infection and AIDS**
- erosive and desquamative syphilis associated with mucositis in setting of AIDS (RR), 1335
- evolution of injectable poly-L-lactic acid from correction of HIV-related facial lipatrophy to aging-related facial contour deficiencies, 1001
- lenalidomide in AIDS-related Kaposi sarcoma (CTR), 210
- liposomal daunorubicin in HIV-related Kaposi's sarcoma (CTR), 212
- PTC299 in HIV-related Kaposi sarcoma (CTR), 211
- syphilis and lues maligna in, a noduloulcerative disease that still lingers after all these centuries (RR), 1072
- Hormonal therapy**, advantages of oral contraceptives and spironolactone for women with acne (DP), 941
- Hyaluronic acid (HA)**
- bilateral comparison study of pimecrolimus cream 1% and ceramide-HA emollient foam in atopic dermatitis, 666
- commentary on rheological evaluation of the physical properties of HA dermal fillers (letter to the editor), 964
- efficacy and tolerability of new monophasic double-crosslinked HA filler for deep lines and wrinkles, 134
- efficacy of cream-based novel formulations of HA of different molecular weights in anti-wrinkle treatment, 990
- guide to temporal fossa augmentation with small gel particle HA dermal filler, 673
- management of impending necrosis associated with soft tissue filler injections (CR), 1007
- new face of fillers: why evidence and experience both count (letter to the editor), 964
- open-label pilot study on effectiveness and safety in lip augmentation, 145
- Restylane for lip augmentation (PP), 684
- rheological evaluation of physical properties of HA dermal fillers, 974
- safety and effectiveness of small and large gel-particle HA in correction of perioral wrinkles, 982
- solid HA tailored to fix fine wrinkles (PP), 1341
- tower technique for injection of, 1277
- Hydrogels**, polyacrylamide, characteristics of different products, 1370
- Hydroquinone**, evaluation of prescription strength 4% hydroquinone/10% L-ascorbic acid treatment system for photodamage in normal to oily skin, 1455
- Hyperdynamic vertical glabellar furrows**, corrugator supercilii muscle terminal nerve ablation using novel thread technique for treatment of, 762
- Hyperhidrosis, axillary**, same-patient prospective comparison and literature review of Botox versus Dysport for (CR), 1013
- Hyperkeratosis** of scalp and alopecia in children of color, 511
- Hyperpigmentation**
- La Roche-Posay introduces new products (PP), 938
- natural therapies for, s11 (September), s15 (September)
- in nephrogenic systemic fibrosis, case report and literature review on (RR), 622
- post-inflammatory, and acne in patients with skin of color, s13 (June)
- post-inflammatory, efficacy and safety of azelaic acid gel 15% in acne and, 586
- post-inflammatory, strategies minimizing, in treatment of acne patients with skin of color (DP), s25 (December)
- Q-switched laser treatment of amiodarone pigmentation (CR), 1316
- Hypersensitivity reactions** during selective serotonin reuptake inhibitor therapy resulting in acquired cutis laxa (RR), 215
- Hypomelanosis**, progressive macular, 502

- I**
- Ibuprofen**, cutaneous reactions to non-steroidal anti-inflammatory drugs, 1160
- IDP-107**, dose-ranging study on safety and efficacy in acne vulgaris (CTR), 426
- Imatinib**
in mucosal or acral/lentiginous melanoma (CTR), 208
pigmentary changes in patient treatment with (CR), 1062
- Imiquimod**
in combination with cryotherapy in treatment of hypertrophic actinic keratosis (CTR), 426
compared to cryotherapy in actinic keratoses, lesion clearance, safety, and skin quality outcomes in, 1432
FDA approves Zyclara Cream 3.75% for external genital warts (PP), 552
Graceway receives FDA approval for Zyclara Cream 2.5% for actinic keratosis (PP), 1076
long-term sustained complete clearance of actinic keratoses of face or balding scalp after treatment with, 165
with Nd:YAG laser for tattoo removal (CTR), 1342
optimal use in keloids (NVR), 548
regression of internal melanoma metastases after topical application of (CR), 302
review of off-label clinical applications, 1300
Taro receives FDA approval for imiquimod 5% cream (PP), 683
treatment of actinic keratosis of face with imiquimod cream followed by photodynamic therapy (CTR), 426
ulcerated nodular nasal basal cell carcinoma successfully treated with imiquimod 5% cream (letter to the editor), 240
- Immune function**
autoimmune-mediated blisters (RR), 491
CD70 and Th17 involvement in human contact sensitivity (BC), 1192
fatal cutaneous strongyloidiasis as side effect of mycophenolate mofetil in pemphigus foliaceus in immunocompromised patient (CR), 418
inflammation in rosacea and acne, and implications for patient care, 586
role of inflammation and immunity in pathogenesis of androgenetic alopecia, 1404
T cell repertoire analysis of immune mediated skin diseases (CTR), 936
- Immunoglobulin, intravenous**, with or without cyclophosphamide in pemphigus (CTR), 1077
- Immunosuppression**
case report of pyoderma gangrenosum following breast reconstructive surgery treated with immunosuppression and adjunctive xenogeneic matrix scaffolds (RR), 545
viral-associated trichodysplasia of, in renal transplant patient (RR), 422
- Impact Factor Ranking** of JDD (editorial), 1234
- Impedance measurements**, evaluation of moisturizing effect of methanolic extract of five medicinal plants incorporated into cream bases using, 1116
- IncobotulinumtoxinA**
FDA approval for glabellar lines (PP), 1076
- treatment of notalgia paresthetica with (CTR), 91
- Inflammation**
efficacy and safety of azelaic acid gel 15% in post-inflammatory hyperpigmentation and acne, 586
post-inflammatory hyperpigmentation and acne in patients with skin of color, s13 (June)
role of inflammation and immunity in pathogenesis of androgenetic alopecia, 1404
in rosacea and acne, implications for patient care, 614
strategies minimizing irritation and iatrogenic post-inflammatory pigmentation in treating acne patients with skin of color (DP), s25 (December)
- Infliximab**, review of psoriasis treatment in 120 patients on therapy for a minimum of one year, 539
- Insulin growth factor-1**, decrease of IGF-1 as novel mechanism for anti-androgen effect of isotretinoin and its association with depression (BC), 793
- Intense pulsed light photorejuvenation**, histological and immunohistochemical evaluation of, 1246
- Interferon**
efficacy of vorinostat in combination with interferon alpha and extracorporeal photopheresis in late stage mycosis fungoides and Sézary syndrome (BC), 403
FDA approves Sylatron to treat melanoma (PP), 684
Helix Biopharma Corp. files clinical hold response on topical interferon alpha-2b (PP), 1478
taurine chloramine inhibits NO and TNF- α production in zymosan plus interferon- γ activated RAW 264.7 cells, 659
- International alliance** of JDD (editorial), 581
- Intravenous immunoglobulin** with or without cyclophosphamide in pemphigus (CTR), 1077
- Iododerma** following radioactive iodine ablation of thyroid for Graves disease (RR), 1070
- Iohexol**, fixed drug eruption associated with intravenous contrast media (CR), 802
- Ipilimumab**, FDA approval of (PP), 552
- Irritation of skin from treatment**
patient experience and management of dryness and irritation from acne treatment, 605
safety and efficacy of micronized tretinoin 0.05% gel in adolescent acne, 647
strategies minimizing irritation and iatrogenic post-inflammatory pigmentation in treating acne patients with skin of color (DP), s25 (December)
in topical rosacea therapy, vehicle formulations affecting, 627
- Isotretinoin**
decrease of insulin growth factor-1 as novel mechanism for anti-androgen effect of isotretinoin and its association with depression (BC), 793
depression associated with, 409
isotretinoin does not prolong QT intervals and QT dispersion in severe acne: a surprising finding for a drug with numerous side effects, 710
- reported adverse effects of systemic corticosteroids and (RR), 287
- J**
- Journal of Drugs in Dermatology**
international alliance of (editorial), 581
receives impact factor ranking of 1.954 (editorial), 1234
- K**
- Kaposi sarcoma, AIDS and HIV-related**
lenalidomide in (CTR), 210
liposomal daunorubicin in (CTR), 212
PTC299 in (CTR), 211
- Keloids**
advances in treatment of, 468
new treatments in (NVR), 548
- Keratinocytes**
clinical evidence for activity of tetrahydroxypropyl ethylenediamine (THPE) as new anti-aging active cosmetic, 1102
treatment of vitiligo with melanocyte-keratinocyte cell suspension versus dermabrasion only in pilot study with 12-month follow-up, 1032
- Keratoacanthoma**, eruptive squamous cell carcinomas with keratoacanthoma-like features in patients treated with sorafenib (CR), 308
- Kidneys**
alefacept therapy for nephrogenic systemic fibrosis (CR), 922
chloracne-like drug eruption associated with sorafenib in metastatic renal cell carcinoma (CR), 1331
clinical clues and patterns in biopsy diagnosis of cutaneous metastases of renal carcinoma (NVR), 678, 930
is chronic cutaneous discoid lupus protective against severe renal disease in systemic lupus erythematosus?, 1413
melanoma in renal transplant patient (RR), 808
nephrogenic systemic fibrosis case report and literature review (RR), 622
randomized-withdrawal phase 3 study on safety and efficacy of nalfurafine HCl (AC-820) for uremic pruritus in renal disease (CTR), 91
viral-associated trichodysplasia of immunosuppression in renal transplant patient (RR), 422
- Koebner phenomenon**, tattoo sites and psoriasis (CR), 1199
- Kojic acid** in natural therapies for hyperpigmentation, s17 (September)
- KRT14 mutation** in epidermolysis bullosa simplex with mottled pigmentation (CR), 926
- L**
- Lanthanum carbonate**, evaluation of efficacy in calciphylaxis (CTR), 1342
- Laser technology**
advances in laser hair removal in skin of color, 1235
Alma Lasers introduces iPixel fractional ablative technology (PP), 805
best practices and evidence-based use of 800 nm diode laser for pseudofolliculitis barbae in skin of color (DP), s20

- (December)
- burn scar appearance after fractional carbon dioxide laser treatment (CTR), 96
- in combined treatment for skin rejuvenation and soft-tissue augmentation of aging face, 125
- comparison of high-fluence single-pass diode laser to low-fluence multiple-pass diode laser for hair reduction with 18 months of follow up, 62
- comparison of sequential treatment with diode and alexandrite lasers versus alexandrite laser alone in hirsutism, 1255
- confocal scanning laser microscopy, 21
- diode 810 nm laser as safe, effective modality to meet a growing population need (DP), s8 (December)
- effects of pulsed-dyed laser on scar formation (CTR), 96
- evaluation of clinical improvement in acne scars and active acne in 1540-nm non-ablative fractional laser treatment, 907
- FDA clearance of PinPointe FootLaser for nail fungus (PP), 104
- FDA grants marketing clearance for HairMax Dual 12 home-use laser phototherapy device (PP), 1341
- fractional laser resurfacing for acne scarring in Fitzpatrick skin types IV–VI (DP), s6 (December)
- laser hair removal in ethnic skin, principles and practical aspects of (DP), s17 (December)
- laser hair removal pearls in skin of color (DP), s12 (December)
- multi-center clinical study and review of fractional ablative carbon dioxide laser resurfacing for rhytides, photoaging, scars, and striae, 352
- multiplexed 1,440 and 1,320 nm fractionated laser for chronic photodamage, 1266
- nonablative 1927 nm fractional resurfacing for actinic keratoses (PP), 103
- novel 0.65 millisecond pulsed 1064 nm laser to treat skin of color without skin cooling or anesthetics (DP), s10 (December)
- promising future of laser and light therapy, 32
- prospective randomized trial on effects of fluence settings in Er:YAG micropeel for facial photoaging, 179
- Q-switched laser treatment of amiodarone pigmentation (CR), 1316
- role in onychomycosis (NVR), 1074
- safety and efficacy of cosmetic laser treatments for skin of color, 35
- safety of tumescent and laser-assisted liposuction, review of literature on, 1363
- topical imiquimod with Nd:YAG laser for tattoo removal (CTR), 1342
- treating lentigines in Asian patients with Q-switched Alexandrite laser (DP), s14 (December)
- treatment of dyschromia with novel 607 nm pulsed-dye laser, 388
- treatment of surgical scars using pulsed dye laser (CTR), 96, 1216
- XTRAC laser for psoriasis (PP), 938
- Latin Americans**, melasma in, 517
- Lenalidomide**
- in AIDS-related Kaposi sarcoma (CTR), 210
- in relapsed mycosis fungoides/Sézary syndrome (CTR), 209
- Lentigines**, treating lentigines in Asian patients with Q-switched Alexandrite laser (DP), s14 (December)
- Letters to the editor**
- commentary on rheological evaluation of the physical properties of hyaluronic acid dermal fillers, 964
- doxycycline versus minocycline for management of acne, 965, 966
- new face of fillers: why evidence and experience both count, 964
- short-term and low-dose oral fluconazole treatment can cause Stevens-Johnson syndrome in HIV-negative patients, 1360
- ulcerated nodular nasal basal cell carcinoma successfully treated with imiquimod 5% cream, 240
- Leukemia**
- clinical clues and patterns in biopsy diagnosis of cutaneous metastases of (NVR), 678, 930
- dasatinib in unresectable or metastatic squamous cell skin cancer or RAI stage 0-1 chronic lymphocytic leukemia (CTR), 207
- Levamisole**
- levamisole induced necrosis of skin and neutropenia following intranasal cocaine use: a newly recognized syndrome (CR), 1204
- retiform purpura from (RR), 217
- Levocetirizine**, and rupatadine in chronic idiopathic urticaria, comparative study of efficacy and safety, 1444
- Levofloxacin**, FDA approves first generic versions of (PP), 1076
- Lice**, FDA approves Natroba for head lice (PP), 434
- Lichen planus** following Tdap vaccination (CR), 1067
- Licorice**
- aesthetic benefits of natural ingredients in skin care, s12 (September)
- in atopic dermatitis and other inflammatory skin diseases, s6 (September)
- evaluation of moisturizing effect of methanolic extract incorporated into cream bases using impedance and extensimetry methods, 1116
- in natural therapies for hyperpigmentation, s17 (September)
- Light emitting diode (LED) systems**
- FDA approval of Syneron LED-based skin rejuvenation system (PP), 435
- self-treatment of mild-to-moderate facial acne with blue light treatment system, 596
- Taenda Luxe device for home treatment of periorbital wrinkles (PP), 1215
- Light therapy**. *See* Phototherapy
- Lip**
- open-label pilot study on effectiveness and safety of hyaluronic acid in lip augmentation, 145
- randomized double-blind placebo-controlled multi-center trial of zinc for herpes simplex labialis (CTR), 1343
- Restylane for lip augmentation (PP), 684
- treatment of actinic cheilitis by photodynamic therapy with 5-aminolevulinic acid and blue light activation, 1240
- Lipoatrophy, facial**, evolution of injectable poly-L-lactic acid from correction of HIV-related facial lipoatrophy to aging-related facial contour deficiencies, 1001
- Lipolysis**, injection lipolysis of abdominal subcutaneous fat yields results (PP), 103
- Liposuction**, safety of tumescent and laser-assisted liposuction, review of literature on, 1363
- Liver cancer**
- clinical clues and patterns in biopsy diagnosis of cutaneous metastases of (NVR), 678, 930
- review of chemopreventative effects of oral retinoids for, 1292
- sorafenib-induced eruptive squamous cell carcinomas with keratoacanthoma-like features in (CR), 308
- Lues maligna**
- erosive and desquamative syphilis associated with mucositis in setting of AIDS (RR), 1335
- a noduloulcerative disease that still lingers after all these centuries (RR), 1072
- Lung cancer**, clinical clues and patterns in biopsy diagnosis of cutaneous metastases (NVR), 678, 930
- Lupus erythematosus**
- FDA approves Benlysta for (PP), 806
- is chronic cutaneous discoid lupus protective against severe renal disease in systemic lupus erythematosus?, 1413
- manifestations and treatment of (NVR), 1212, 1474
- LY2439821** in moderate-to-severe psoriasis (CTR), 94
- Lymph nodes**, comparison of elective lymph node treatment versus clinical observation in absence of palpable lymph nodes in high risk squamous cell carcinoma (CTR), 207
- Lymphadenoma**, cutaneous, Mohs micrographic surgery for (CR), 1324
- Lymphoma**
- clinical clues and patterns in biopsy diagnosis of cutaneous metastases of (NVR), 678, 930
- diffuse large B-cell lymphoma associated with biologic and other investigational agents in psoriasis (CR), 80
- Pralatrexate in Patients with Relapsed or Refractory Peripheral T-Cell Lymphoma (PROPEL) (PP), 213
- review of chemopreventative effects of oral retinoids for cutaneous T cell lymphoma, 1292
- study evaluating two dose levels of Targretin capsules in refractory cutaneous T-cell lymphoma (CTR), 209
- M**
- Mallow**, evaluation of moisturizing effect of methanolic extract incorporated into cream bases using impedance and extensimetry methods, 1116
- Marsh horsetail**, evaluation of moisturizing effect of methanolic extract incorporated into cream bases using impedance and extensimetry methods, 1116
- Matrix scaffolds, xenogenic**, case report of pyoderma gangrenosum following breast reconstructive surgery treated with immunosuppression and (RR), 545

- Mechlorethamine hydrochloride**, New Drug Application for (PP), 1478
- Medication choice**, and associated health care outcomes and costs in acne and acne-related conditions, 766
- Medicinal plants**
- comparative study of safety and efficacy of 75% mulberry extract oil versus placebo as topical treatment for melasma, 1025
 - evaluation of moisturizing effect of methanolic extract of five medicinal plants incorporated into cream bases using impedance and extensimetry methods, 1116
 - randomized double-blind petrolatum-controlled study on efficacy of oregano extract ointment in wound healing, 1168
- MelaFind skin cancer detection device**
- comparison of diagnostic and biopsy/referral sensitivity to melanoma between dermatologists and MelaFind (RS), 1078
 - FDA gives provisional approval to (PP), 1340
 - FDA panel votes in favor of (PP), 213
- Melanin synthesis**, s16 (September)
- Melanocytes**, treatment of vitiligo with melanocyte-keratinocyte cell suspension versus dermabrasion only in pilot study with 12-month follow-up, 1032
- Melanoma**
- clinical clues and patterns in biopsy diagnosis of cutaneous metastases (NVR), 678, 930
 - comparison of diagnostic and biopsy/referral sensitivity to melanoma between dermatologists and MelaFind (RS), 1078
 - dasatinib in locally advanced or metastatic mucosal melanoma, acral melanoma, or solar melanoma that cannot be removed by surgery (CTR), 208
 - detection by oblique-incidence optical spectroscopy (CTR), 318
 - early detection and cure in serial screening program, 244
 - FDA approves Sylatron to treat (PP), 684
 - FDA gives provisional approval to MelaFind device (PP), 1340
 - FDA panel votes in favor of MelaFind skin cancer detection device (PP), 213
 - imatinib in mucosal or acral/lentiginous melanoma (CTR), 208
 - lessons from an exemplary physician in private setting (editorial), 238
 - new drug applications for vemurafenib in advanced skin cancer (PP), 805
 - positive results in PLX4032 study (PP), 103
 - regression of internal melanoma metastases after topical application of imiquimod (CR), 302
 - in renal transplant patient (RR), 808
 - as second cancer (NVR), 320
 - second cancers after (NVR), 320
 - sorafenib and temsirolimus in metastatic, recurrent, or unresectable melanoma (CTR), 207
 - study confirms sunscreen prevents (PP), 213
 - trends in treatment and detection of skin cancer, 16
 - use of gelatin sponges in Mohs micrographic surgery and staged melanoma excision, 68
- Melanosome transfer**, s16 (September)
- Melasma**
- comparative study of safety and efficacy of 75% mulberry extract oil versus placebo as topical treatment for, 1025
 - comparison of 1% tretinoin peeling versus 70% glycolic acid peeling in female patients with, 1439
 - in Latin Americans, 517
 - pilot study using reflectance confocal microscopy in assessment of novel formulation for, 1260
- Mercury**, FDA bans skin whitening products containing (PP), 1215
- Merkel cell carcinoma**, as banal-appearing aggressive actor (NVR), 811
- Metabolic syndrome** and surrogate markers of increased cardiovascular risk in children with moderate-to-severe psoriasis compared to age-matched population with warts (BC), 900
- Metallic taste** as side effect of topical fluorouracil, 1201
- Metastases**
- biopsy diagnosis: clinical clues and patterns to help distinguish cutaneous metastases (NVR), 678, 930
 - dasatinib in unresectable or metastatic squamous cell skin cancer or RAI stage 0-1 chronic lymphocytic leukemia (CTR), 207
 - regression of internal melanoma metastases after topical application of imiquimod (CR), 302
- Methanolic extract**, evaluation of moisturizing effect of methanolic extract of five medicinal plants incorporated into cream bases using impedance and extensimetry methods, 1116
- Methemoglobinemia** risk from benzocaine topical products (PP), 684
- Methicillin-resistant *Staphylococcus aureus***, FDA approves Ceftaroline for (PP), 104
- Methyl aminolevulinic acid (MAL)**, safety and efficacy comparison of blue versus red light sources for MAL-PDT in photodamaged skin, 53
- Metronidazole**
- in novel rosacea treatment system, investigator-blind randomized parallel-group study on, 1179
 - in topical rosacea therapy, vehicle formulations for, 627
- Micro-dosing system**, CoreRx Pharmaceuticals introduces Xcelodose micro-dosing system (PP), 1478
- Migraine**, chronic, FDA approves Botox for (PP), 104
- Minocycline**
- in combination treatment for moderate-to-severe acne (CTR), 90
 - compared to doxycycline for management of acne (letter to the editor), 965, 966
- Minoxidil**, ROGAINE introduces Unscented Topical Foam (PP), 1076
- Mohs micrographic surgery**
- for cutaneous lymphadenoma (CR), 1324
 - three-dimensional technique as new concept, 1273
 - triage in, 257
 - use of gelatin sponges in, and secondary wound healing, 68
- Moisturizers**
- evaluation of moisturizing effect of methanolic extract of five medicinal plants incorporated into cream bases using impedance and extensimetry methods, 1116
 - new body moisturizer increases skin hydration and improves AD symptoms in children and adults, 714
 - in novel rosacea treatment system, investigator-blind randomized parallel-group study on, 1179
 - over-the-counter moisturizer compared to prescription barrier creams in mild-to-moderate atopic dermatitis of children, 531
- Monoclonal antibodies**, study of human monoclonal antibody (zanolimumab) to treat mycosis fungoides and Sézary syndrome (CTR), 1077
- Muckle-Wells syndrome**, severe, anakinra effective for (PP), 214
- Mucositis**, erosive, and desquamative syphilis, in setting of AIDS (RR), 1335
- Mulberry**
- aesthetic benefits of natural ingredients in skin care, s11 (September)
 - comparative study of safety and efficacy of 75% mulberry extract oil versus placebo as topical treatment for melasma, 1025
- Mupirocin**, FDA approval of Glenmark Generics mupirocin 2% ointment (PP), 939
- Mycobacterial infection**
- Mycobacterium fortuitum* infection following adalimumab treatment for psoriasis and subsequent complication-free treatment with alternate TNF- α blockers (CR), 914
 - thalidomide and complement activation by *M. leprae*, 274
- Mycophenolate mofetil** in pemphigus foliaceus, fatal cutaneous strongyloidiasis as side effect of (CR), 418
- Mycosis fungoides/Sézary syndrome**
- efficacy of vorinostat in combination with interferon alpha and extracorporeal photopheresis in late stage of (BC), 403
 - gemcitabine and pemetrexed disodium in advanced stage of (CTR), 210
 - lenalidomide in relapse of (CTR), 209
 - new analysis demonstrates activity in relapsed or refractory transformed mycosis fungoides (PP), 213
 - study of human monoclonal antibody (zanolimumab) in (CTR), 1077
 - study of total skin electron beam therapy in stage IB-IIIa mycosis fungoides (CTR), 209
 - T cell repertoire analysis of immune mediated skin diseases (CTR), 936

N

Naftifine 2% cream

- double-blind randomized vehicle-controlled study on efficacy and safety in tinea cruris, 1142
- double-blind randomized vehicle-controlled study on efficacy and safety in tinea pedis, 1282

Nail disorders

- clinical evaluation of safety and efficacy of new topical treatment for onychomycosis, 1186
- FDA clearance of PinPointe FootLaser for onychomycosis (PP), 104
- role of lasers in onychomycosis (NVR), 1074
- Nalfurafine HCl (AC-820)**, randomized-withdrawal phase 3 study on safety and efficacy in hemodialysis and uremic pruritus (CTR), 91
- Nalmefene**, efficacy, safety, and tolerability of SRD174 cream for pruritus in atopic dermatitis, 853
- Nanotechnology**, and dermatology education in United States, data from pilot survey, 1037
- Nasal basal cell carcinoma**, ulcerated nodular, successfully treated with imiquimod 5% cream (letter to the editor), 240
- Nasolabial folds and wrinkles**, azficel-T in (PP), 325
- Natural ingredients**
- aesthetic benefits of, s10 (September)
 - in atopic dermatitis and other inflammatory skin diseases, s6 (September)
- CME: identifying natural ingredients and their use in skin care, s4 (September), s21 (September), s22 (September)
- comparative study of safety and efficacy of 75% mulberry extract oil versus placebo as topical treatment for melasma, 1025
- cosmeceutical and nutraceutical horizons, 24
- defining terms in, s10 (September)
- evaluation of moisturizing effect of methanolic extract of five medicinal plants incorporated into cream bases using impedance and extensimetry methods, 1116
- in hyperpigmentation, s11 (September), s15 (September)
- randomized double-blind petrolatum-controlled study on efficacy of oregano extract ointment in wound healing, 1168
- Stiefel/GSK introduces Illuminisse Brightening Complex (PP), 938
- Nd:YAG laser** and topical imiquimod for tattoo removal (CTR), 1342
- Necrosis**
- green tea extract protects human skin fibroblasts from reactive oxygen species induced necrosis, 1096
 - levamisole induced necrosis of skin and neutropenia following intranasal cocaine use: a newly recognized syndrome (CR), 1204
 - management of impending necrosis associated with soft tissue filler injections (CR), 1007
- Neodymium:YAG laser** and topical imiquimod for tattoo removal (CTR), 1342
- Neonates**, phototherapy-induced purpura in transient porphyria of (RR), 306
- Neoplasia**
- biopsy diagnosis: clinical clues and patterns to help distinguish cutaneous metastases (NVR), 678, 930
 - cancer: this war is personal (editorial), 237
 - clinical trial of Dermacorder for detecting malignant skin lesions (CTR), 317
 - comparison of diagnostic and biopsy/referral sensitivity to melanoma between dermatologists and MelaFind (RS), 1078
 - comparison of elective lymph node treatment versus clinical observation in absence of palpable lymph nodes in high risk squamous cell carcinoma (CTR), 207
 - confocal microscopy of cutaneous neoplasms and normal skin (CTR), 318
 - dasatinib in locally advanced or metastatic mucosal melanoma, acral melanoma, or solar melanoma that cannot be removed by surgery (CTR), 208
 - dasatinib in unresectable or metastatic squamous cell skin cancer or RAI stage 0-1 chronic lymphocytic leukemia (CTR), 207
 - early detection and cure in serial screening for melanoma, 244
 - FDA approves Gardasil to prevent anal cancer (PP), 325
 - FDA gives provisional approval to MelaFind device (PP), 1340
 - FDA panel votes in favor of MelaFind skin cancer detection device (PP), 213
 - imatinib in mucosal or acral/lentiginous melanoma (CTR), 208
 - lenalidomide in AIDS-related Kaposi sarcoma (CTR), 210
 - lessons from an exemplary physician in private setting (editorial), 238
 - liposomal daunorubicin in HIV-related Kaposi's sarcoma (CTR), 212
 - melanoma detection by oblique-incidence optical spectroscopy (CTR), 318
 - melanoma in renal transplant patient (RR), 808
 - melanoma risk after other cancer diagnosis (NVR), 320
 - Merkel cell carcinoma as banal-appearing aggressive actor (NVR), 811
 - Mohs micrographic surgery for cutaneous lymphadenoma, 1324
 - new drug applications for vemurafenib in advanced skin cancer (PP), 805
 - novel devices for diagnosis and treatment, 21
 - phase 2 trial of erlotinib prior to surgery or radiation in squamous cell cancer of skin (CTR), 207
 - positive results in PLX4032 melanoma study (PP), 103
 - PTC299 in HIV-related Kaposi sarcoma (CTR), 211
 - regression of internal melanoma metastases after topical application of imiquimod (CR), 302
 - review of chemopreventative effects of oral retinoids for internal neoplasms, 1292
 - review of off-label clinical applications of imiquimod, 1300
 - second cancers after melanoma (NVR), 320
 - sorafenib and temsirolimus in metastatic, recurrent, or unresectable melanoma (CTR), 207
 - sorafenib-induced eruptive squamous cell carcinomas with keratoacanthoma-like features in hepatocellular carcinoma (CR), 308
 - spectral diagnosis of cutaneous malignancy (CTR), 318
 - study confirms sunscreen prevents melanoma (PP), 213
 - study evaluating two dose levels of Targretin capsules in refractory cutaneous T-cell lymphoma (CTR), 209
 - study of ultrasonography with elastography in skin neoplasms (CTR), 319
 - in tattoo site, case of dermatofibrosarcoma protuberans and review of literature, 837
 - three-dimensional Mohs surgery, a new concept, 1273
 - trends in treatment and detection of skin cancer, 16
 - triage in Mohs micrographic surgery, 257
 - ulcerated nodular nasal basal cell carcinoma successfully treated with imiquimod 5% cream (letter to the editor), 240
 - use of gelatin sponges in Mohs micrographic surgery and staged melanoma excision, 68
 - winning poster: predictive factors for severity of scar formation after skin cancer surgeries (RS), 810
- Nephrogenic systemic fibrosis**
- alefacept therapy for (CR), 922
 - case report and literature review (RR), 622
- Neuroblastoma**, review of chemopreventative effects of oral retinoids for, 1292
- Neurofibromatosis**, eruptive plexiform schwannomas in child with neurofibromatosis I (RR), 1210
- Neurotoxins**. *See also* Botulinum toxin
- cosmeceutical and nutraceutical horizons, 24
 - topical neurotoxin erases crow's feet (PP), 1341
- Neutropenia**, levamisole induced necrosis of skin and neutropenia following intranasal cocaine use: a newly recognized syndrome (CR), 1204
- News, Views and Reviews (NVR)**
- biopsy diagnosis: clinical clues and patterns to help distinguish cutaneous metastases, 678, 930
 - genes in psoriasis in 2011, where are we now?, 1337
 - manifestations and treatment of cutaneous lupus erythematosus, 1212, 1474
 - Merkel cell carcinoma as banal-appearing aggressive actor, 811
 - onychomycosis: is there a role for lasers, 1074
 - second cancers after melanoma and malignancies with risk for melanoma, 320
 - what's new in androgenetic alopecia: approvals, long-term safety data, cancer risk, and treatment options for women, 98
 - what's new in keloid treatment: new applications for common therapies, new treatments to come, 548
 - wound healing: from basic science to clinical practice and beyond, 427
- Nitric oxide**, taurine chloramine inhibits NO and TNF- α production in zymosan plus interferon- γ activated RAW 264.7 cells, 659
- Nitrogen, liquid**, compared to dimethyl ether and propane in cryosurgical treatment of warts, case report and review of literature on, 1174
- Nitroglycerin**, FDA approval for Rectiv (PP), 939
- Non-steroidal anti-inflammatory agents**, cutaneous reactions to, 1160
- Notalgia paresthetica** treatment with Xeomin (CTR), 91
- Nova Southeastern University College of**

Osteopathic Medicine and Broward General Medical Center Dermatology Residency Training Program
 autoimmune-mediated blisters (for the Boards) (RR), 491
 case report on pyoderma gangrenosum following breast reconstructive surgery treated with immunosuppression and adjunctive xenogeneic matrix scaffolds (RR), 545
 program spotlight on (RR), 467

Nutrition
 cosmeceutical and nutraceutical horizons, 24
 phase 2 double-blind randomized placebo-controlled trial of novel nutritional supplement product to promote health skin, 1106
 randomized placebo-controlled double-blind study on efficacy of citrus bioflavonoid blend in senile purpura, 718

O

Oatmeal, colloidal, in atopic dermatitis and other inflammatory skin diseases, s6 (September)

Oblique-incidence optical spectroscopy, melanoma detection by (CTR), 318

Olive
 aesthetic benefits of natural ingredients in skin care, s13 (September)
 evaluation of moisturizing effect of methanolic extract incorporated into cream bases using impedance and extensimetry methods, 1116

OnabotulinumtoxinA (ONA)
 Allergan cell-based assay for BOTOX (PP), 938
 comparing clinical attributes of abobotulinumtoxinA and ONA using Frontalis Rating Scale and Frontalis Activity Measurement Standard, 1148
 FDA approves Botox for chronic migraine (PP), 104
 in moderate-to-severe glabellar lines, rapid onset of response and patient-reported outcomes in, 39

Onychomycosis
 clinical evaluation of safety and efficacy of new topical treatment for, 1186
 FDA clearance of PinPointe FootLaser for (PP), 104
 role of lasers in (NVR), 1074

Optical coherence tomography, novel devices for diagnosis and treatment of skin disease, 21

Optical spectroscopy, oblique-incidence, melanoma detection by (CTR), 318

Oregano extract ointment, randomized double-blind petrolatum-controlled study on efficacy in wound healing, 1168

Organic products, use of term, s10 (September)

Orthopedic implants, intralymphatic histiocytosis associated with (RR), 1208

Ovarian cancer, clinical clues and patterns in biopsy diagnosis of cutaneous metastases of (NVR), 678, 930

Oxidative stress
 assessment of antioxidative capacity kinetics of topical antioxidants, 262
 complementary antioxidant function of caffeine and green tea polyphenols in normal human skin fibroblasts,

753
 green tea extract protects human skin fibroblasts from reactive oxygen species induced necrosis, 1096

P

Pachyonychia congenita, small interfering RNAs in, 28

Pain management
 in debridement of leg ulcers (PP), 324
 FDA approval of Rectiv for pain associated with anal fissures (PP), 939
 novel 0.65 millisecond pulsed 1064 nm laser to treat skin of color without skin cooling or anesthetics (DP), s10 (December)

Pediatric dermatology
 comparing Cetaphil Restoraderm System versus standard skin care in infants with atopic dermatitis (CTR), 1486
 comparison of OTC moisturizer and prescription barrier creams in mild-to-moderate atopic dermatitis of children, 531
 Epiduo pediatric acne study (CTR), 90, 312
 eruptive plexiform schwannomas in child with neurofibromatosis I (RR), 1210
 metabolic syndrome and surrogate markers of increased cardiovascular risk in children with moderate-to-severe psoriasis compared to age-matched population with warts (BC), 900
 new body moisturizer increases skin hydration and improves atopic dermatitis symptoms in children and adults, 714
 novel KRT14 mutation in epidermolysis bullosa simplex with mottled pigmentation (CR), 926
 pediatric longitudinal evaluation on long-term safety of Protopic Ointment for atopic dermatitis (CTR), 1217
 pediatric vascular anomalies (RR), 893
 rituximab dosing in refractory pemphigus vulgaris in adolescent male (CR), 202
 safety and efficacy of LEO 80185 topical suspension in adolescents with scalp psoriasis (CTR), 95
 scalp hyperkeratosis and alopecia in children of color, 511
 XTRAC laser for psoriasis (PP), 938

Peginterferon alfa-2b, FDA approves Sylatron to treat melanoma (PP), 684

Pemetrexed disodium and gemcitabine in advanced mycosis fungoides or Sézary syndrome (CTR), 210

Pemphigoid, bullous, after herpes zoster vaccine administration (CR), 1328

Pemphigus foliaceus, fatal cutaneous strongyloidiasis as side effect of mycophenolate mofetil treatment in (CR), 418

Pemphigus vulgaris
 randomized trial of intravenous immunoglobulin with or without cyclophosphamide in (CTR), 1077
 refractory, rituximab dosing in adolescent male (CR), 202

Perioral wrinkles, safety and effectiveness of small and large gel-particle hyaluronic acid in correction of, 982

Periorbital wrinkles, Taenda Luxe Device for home treatment of (PP), 1215

PH-10, Provectus Pharmaceuticals phase 2C clinical trial of PH-10 for psoriasis (PP), 806

Photoaging
 comparison of retinol 1.0% and tretinoin 0.02% in moderate-to-severe photodamage and wrinkles (CTR), 1217
 evaluation of prescription strength 4% hydroquinone/10% L-ascorbic acid treatment system for photodamage in normal to oily skin, 1455
 multi-center clinical study and review of fractional ablative carbon dioxide laser resurfacing for rhytides, photoaging, scars, and striae, 352
 multiplexed 1,440 and 1,320 nm fractionated laser for chronic photodamage, 1266
 prospective randomized trial on effects of fluence settings in Er:YAG micropeel for facial photoaging, 179
 safety and efficacy comparison of blue versus red light sources for MAL-PDT in photodamaged skin, 53
 safety and efficacy of calcium hydroxylapatite for rejuvenation of aging hand, 47

Photodynamic therapy (PDT)
 effect of retinoid pretreatment on outcomes of PDT for actinic keratosis of hand and forearm, 1124
 in onychomycosis (NVR), 1074
 preliminary results of hidradenitis suppurativa treatment with ALA-PDT, 381
 prospective case-based assessment of sequential therapy with topical fluorouracil cream and ALA-PDT for actinic keratosis, 372
 randomized blinded bilateral intraindividual vehicle-controlled trial of PDT with 5-aminolevulinic acid and blue light for actinic keratoses of upper extremities, 1049
 safety and efficacy comparison of blue versus red light sources for MAL-PDT in photodamaged skin, 53
 severe cutaneous reaction to PDT with blue light (CR), 1057
 treatment of actinic cheilitis by ALA-PDT and blue light activation, 1240
 treatment of actinic keratosis of face with imiquimod cream followed by (CTR), 426
 trends in treatment of skin cancer, 17

Photographs, importance of before and after photographs to practice (DP), 940

Photomedicine board review facts (RR), 750

Photopheresis, efficacy of vorinostat in combination with interferon alpha and extracorporeal photopheresis in late stage mycosis fungoides and Sézary syndrome (BC), 403

Phototherapy
 adalimumab plus narrowband ultraviolet B light phototherapy for moderate to severe psoriasis, 366
 FDA approval of Syneron LED-based skin rejuvenation system (PP), 435
 FDA grants marketing clearance for HairMax Dual 12 home-use laser phototherapy device (PP), 1341
 histological and immunohistochemical evaluation of intense pulsed light photorejuvenation, 1246

promising future of laser and light therapy, 32
 randomized blinded bilateral intraindividual vehicle-controlled trial of photodynamic therapy with 5-aminolevulinic acid and blue light for actinic keratoses of upper extremities, 1049
 safety and efficacy comparison of blue versus red light sources for MAL-PDT in photodamaged skin, 53
 self-treatment of mild-to-moderate facial acne with blue light treatment system, 596
 severe cutaneous reaction to photodynamic therapy with blue light (CR), 1057
 Taenda Luxe device for home treatment of periorbital wrinkles (PP), 1215
 in transient porphyria of neonate, purpura in (RR), 306
 treatment of actinic cheilitis by photodynamic therapy with 5-aminolevulinic acid and blue light activation, 1240
 XTRAC laser for psoriasis (PP), 938

Pigmentation

comparative study of safety and efficacy of 75% mulberry extract oil versus placebo as topical treatment for melasma, 1025
 comparison of 1% tretinoin peeling versus 70% glycolic acid peeling in female patients with melasma, 1439
 effectiveness of topical tacrolimus for vitiligo in skin of color patients, 507
 efficacy and safety of azelaic acid gel 15% in post-inflammatory hyperpigmentation and acne, 586
 melasma in Latin Americans, 517
 natural therapies for hyperpigmentation, s11 (September), s15 (September)
 novel KRT14 mutation in epidermolysis bullosa simplex with mottled pigmentation (CR), 926
 pigmentary changes in patient treatment with imatinib (CR), 1062
 pilot study using reflectance confocal microscopy in assessment of novel formulation for melasma, 1260
 progressive macular hypomelanosis, 502
 Q-switched laser treatment of amiodarone pigmentation (CR), 1316
 strategies minimizing irritation and iatrogenic post-inflammatory pigmentation in treating acne patients with skin of color (DP), s25 (December)
 topical retinoids for pigmented skin, 483
 treating lentigines in Asian patients with Q-switched Alexandrite laser (DP), s14 (December)
 treatment of vitiligo with melanocyte-keratinocyte cell suspension versus dermabrasion only in pilot study with 12-month follow-up, 1032

Pimecrolimus

bilateral comparison study of pimecrolimus cream 1% and medical device cream in atopic dermatitis, 735
 bilateral comparison study of pimecrolimus cream 1% and medical device emollient foam in atopic dermatitis, 666

Pipeline Previews (PP)

Abbott files for 510(k) clearance for vitamin D assay, 684
 Abbott withdraws briakinumab from FDA

review (PP), 435
 Acanya gel acne therapy available in pump, 1479
 Allergan cell-based assay for BOTOX, 938
 Alma Lasers introduces iPixel fractional ablative technology, 805
 anakinra effective for severe Muckle-Wells syndrome, 214
 Cardium Therapeutics announces FDA 510(k) clearance for Excellagen, 1478
 Cleure launches FDA-approved broad-spectrum sunscreen, 1076
 CoreRx Pharmaceuticals introduces Xcelodose micro-dosing system, 1478
 Crutchfield Dermatology now offers Selphyl wrinkle treatment, 213
 Ellman International introduces Pellevé to European market, 938
 EndyMed Medical receives FDA clearance for Fractional Skin Resurfacing Applicator, 435
 Eucerin launches campaign in Europe and Asia, 1076
 FDA approves Benlysta for lupus erythematosus, 806
 FDA approves Botox for chronic migraine, 104
 FDA approves Ceftaroline for MRSA, 104
 FDA approves Fibrocell Science LAVIV, 939
 FDA approves first generic versions of levofloxacin, 1076
 FDA approves Gardasil to prevent anal cancer, 325
 FDA approves Glenmark Generics mupirocin 2% ointment, 939
 FDA approves ipilimumab, 552
 FDA approves Natroba for head lice, 434
 FDA approves Rectiv (nitroglycerin) ointment, 939
 FDA approves Rituxan with corticosteroids for severe vasculitis, 683
 FDA approves Sorilux (calcipotriene) foam, 103
 FDA approves Sylatron to treat melanoma, 684
 FDA approves Syneron LED-based skin rejuvenation system, 435
 FDA approves Xeomin (incobotulinumtoxinA), 1076
 FDA approves Zyclara Cream 3.75% for external genital warts, 552
 FDA bans skin whitening products containing mercury, 1215
 FDA clearance of PinPointe FootLaser for nail fungus, 104
 FDA gives provisional approval to MelaFind device, 1340
 FDA grants clearance for HairMax Dual 12 home-use laser phototherapy device, 1341
 FDA panel votes in favor of MelaFind skin cancer detection device, 213
 FDA warning letter to Jaba Labs, 552
 Fibrocell Science, Inc. and azficel-T, 325, 939
 Genentech submits New Drug Application to FDA, 1340
 Gly-Sal Acne Body Spray, 434
 Graceway receives FDA approval for Zyclara Cream 2.5% for actinic keratosis, 1076
 Helix Biopharma Corp. files clinical hold response on topical interferon alpha-2b, 1478
 herpes zoster vaccine reduces zoster risk, 324

injection lipolysis of abdominal subcutaneous fat yields results, 103
 La Roche-Posay introduces new products, 938
 LEO Pharma launches \$0 copay program for Taclonex plaque psoriasis treatments, 683
 long-term efficacy and potencies of botulinum toxin A and B, 324
 management of pain associated with debridement of leg ulcers, 324
 methemoglobinemia risk from benzocaine topical products, 684
 new analysis demonstrates activity in relapsed or refractory transformed mycosis fungoides, 213
 New Drug Application for vemurafenib in advanced skin cancer, 805
 New Drug Application for Yaupon's mechlorethamine hydrochloride, 1478
 nonablative 1927 nm fractional resurfacing for actinic keratoses, 103
 positive results in advanced melanoma drug study, 103
 Provectus Pharmaceuticals phase 2C clinical trial of PH-10 for psoriasis, 806
 psoriasis drug not linked to increased heart risks, 1215
 Restylane for lip augmentation, 684
 resveratrol-containing gel for acne, 434
 ROGAINE introduces Unscented Topical Foam, 1076
 Safe Cosmetics Act of 2011, 1215
 Sagent Pharmaceuticals announces FDA approval of bupivacaine hydrochloride injection, 1478
 Sanuwave Health, Inc. dermaPACE device for diabetic foot ulcers, 325
 solid hyaluronic acid tailored to fix fine wrinkles, 1341
 Stiefel/GSK introduces Illuminisse Brightening Complex, 938
 study confirms sunscreen prevents melanoma, 213
 Syneron devices at 22nd World Congress of Dermatology, 805
 Taenda Luxe Device for home treatment of periorbital wrinkles, 1215
 Taro receives FDA approval for imiquimod 5% cream, 683
 topical neurotoxin erases crew's feet, 1341
 Topix Pharmaceuticals, Inc. releases Replenix ResurFIX Skin Barrier Healing Ointment, 805
 XTRAC laser for psoriasis, 938
 Zelboraf (vemurafenib) receives FDA approval, 1215
PLX4032, positive results in melanoma study (PP), 103
Poly-L-lactic acid (PLLA), evolution of injectable PLLA from correction of HIV-related facial lipoatrophy to aging-related facial contour deficiencies, 1001
Polyacrylamide hydrogels, characteristics of different products, 1370
Polyangiitis, microscopic, FDA approval of Rituxan with corticosteroids for (PP), 683
Polyphenols, green tea
 aesthetic benefits of natural ingredients in skin care, s12 (September)
 complementary antioxidant function of caffeine and green tea polyphenols in normal human skin fibroblasts,

- 753
- Pomegranate**, aesthetic benefits of natural ingredients in skin care, s12 (September)
- Porphyrimemia of neonate**, transient, phototherapy-induced purpura in (RR), 306
- Post-herpetic itch** resolved with gabapentin (CR), 85
- Post-inflammatory hyperpigmentation** and acne in patients with skin of color, s13 (June)
- efficacy and safety of azelaic acid gel 15% in post-inflammatory hyperpigmentation and acne, 586
- strategies minimizing irritation and iatrogenic post-inflammatory pigmentation in treating acne patients with skin of color (DP), s25 (December)
- Povidone-iodine**, chemical burn from (CR), 414
- Pralatrexate** in Patients with Relapsed or Refractory Peripheral T-Cell Lymphoma (PROPEL) (PP), 213
- Prevention**
- FDA approves Gardasil to prevent anal cancer (PP), 325
- review of chemopreventative effects of oral retinoids for internal neoplasms, 1292
- study confirms sunscreen prevents melanoma (PP), 213
- PROPEL** (Pralatrexate in Patients with Relapsed or Refractory Peripheral T-Cell Lymphoma) (PP), 213
- Prurigo nodularis**, CC-10004 for (CTR), 91
- Pruritus**
- acupressure for pruritus in atopic dermatitis (CTR), 90
- CC-10004 for prurigo nodularis (CTR), 91
- efficacy, safety, and tolerability of topical nalmefene for pruritus in atopic dermatitis, 853
- efficacy of fluocinonide cream 0.1% in reducing itch in atopic dermatitis (CTR), 1486
- post-herpetic itch resolved with gabapentin (CR), 85
- randomized-withdrawal phase 3 study on safety and efficacy of nalfurafine HCl (AC-820) in hemodialysis and uremic pruritus (CTR), 91
- treatment of notalgia paresthetica with Xeomin (CTR), 91
- Pseudofolliculitis barbae**
- best practices and evidence-based use of 800 nm diode laser for pseudofolliculitis barbae in skin of color (DP), s20 (December)
- safety and efficacy of laser hair removal in, 35
- Psoriasis**
- Abbott withdraws briakinumab from FDA review (PP), 435
- adalimumab plus narrowband ultraviolet B light phototherapy for moderate to severe psoriasis, 366
- assessment of national trends in acitretin treatment of, 873
- association of depression with acitretin in, 409
- Bicillin-LA versus placebo for chronic plaque-type psoriasis unresponsive to topical medications (CTR), 317
- central serous chorioretinopathy associated with topical corticosteroids in (CR), 918
- CP-690-550 ointment for chronic plaque psoriasis (CTR), 316
- diffuse large B-cell lymphoma associated with biologic and other investigational agents in (CR), 80
- dose finding study of AEB071 assessing psoriasis area and severity index in plaque psoriasis (CTR), 92
- dose-ranging study of AIN457 in moderate-to-severe chronic plaque-type psoriasis (CTR), 93
- efficacy and side effects of low-dose acitretin in (CTR), 95
- FDA approval of Sorilux (calcipotriene) foam in (PP), 103
- frequency of thrombocytopenia in tumor necrosis factor- α inhibitor treatment, 280
- genes in (NVR), 1337
- impact of biologics on disease and treatment burden of, 189
- increased prevalence of psychiatric disorders and health care-associated costs in moderate-to-severe psoriasis, 843
- LEO Pharma launches \$0 copay program for Taclonex plaque psoriasis treatments (PP), 683
- literature review on acitretin in, 772
- long-term study to evaluate safety and tolerability of CP-690,550 in moderate-to-severe chronic plaque psoriasis (CTR), 94
- metabolic syndrome and surrogate markers of increased cardiovascular risk in children with moderate-to-severe psoriasis compared to age-matched population with warts (BC), 900
- multi-center open-label study on safety and efficacy of sequential treatment regimen of clobetasol propionate spray followed by calcitriol ointment in plaque psoriasis, 158
- Mycobacterium fortuitum* infection following adalimumab treatment for psoriasis and subsequent complication-free treatment with alternate TNF- α blockers (CR), 914
- one-year study on efficacy and safety of CP-690,550 for moderate-to-severe chronic plaque psoriasis (CTR), 688
- open-label prospective cohort pilot study on efficacy and safety of etanercept in moderate to severe plaque psoriasis in patients without adequate response to adalimumab, 396
- Provectus Pharmaceuticals phase 2C clinical trial of PH-10 for psoriasis (PP), 806
- psoriasis drugs not linked to increased heart risks (PP), 1215
- randomized controlled trial on clobetasol propionate 0.05% spray for moderate-to-severe plaque psoriasis of scalp, 885
- randomized study of PH-10 for (CTR), 315
- retrospective study of racial and ethnic variations in psoriasis treatment with etanercept, 866
- review of chemopreventative effects of oral retinoids for internal neoplasms in, 1292
- review of infliximab treatment in 120 patients on therapy for a minimum of one year, 539
- safety and efficacy of LEO 80185 topical suspension in adolescents with scalp psoriasis (CTR), 95
- safety and efficacy of secukinumab compared to etanercept in moderate-to-severe chronic plaque-type psoriasis (CTR), 1216
- salicylic acid 6% in ammonium lactate emollient foam vehicle for scalp psoriasis, 270
- study of clinical activity, safety, and tolerability of SRT2104 in moderate-to-severe plaque-type psoriasis (CTR), 92, 314
- study of LY2439821 in moderate-to-severe psoriasis (CTR), 94
- study to assess VB-201 in (CTR), 93, 316
- study to evaluate safety and effectiveness of oral apremilast (CC-10004) in moderate-to-severe plaque psoriasis (CTR), 1487
- study to explore efficacy and safety of ASP015K in moderate-to-severe psoriasis (CTR), 93, 315
- T cell repertoire analysis of immune mediated skin diseases (CTR), 936
- tattoo sites and (CR), 1199
- topical calcipotriene 0.005% and betamethasone dipropionate 0.064% maintains efficacy of etanercept after step-down dose in moderate-to-severe plaque psoriasis, 878
- XTRAC laser for (PP), 938
- Yin-Yang strategy: proposing a new effective repeatable sequential therapy for, 831
- PSORS genes** in psoriasis (NVR), 1337
- Psychiatric disorders**, increased prevalence of psychiatric disorders and health care-associated costs in moderate-to-severe psoriasis, 843
- PTC299** in HIV-related Kaposi sarcoma (CTR), 211
- Pulsed dye laser**
- effects on scar formation (CTR), 96
- laser treatment of dyschromia with novel 607 nm pulsed-dye laser, 388
- treatment of surgical scars using (CTR), 96, 1216
- Purpura**
- phototherapy-induced, in transient porphyrimemia of neonate (RR), 306
- randomized placebo-controlled double-blind study on efficacy of citrus bioflavanoid blend in senile purpura, 718
- retiform, levamisole-induced (RR), 217
- Pyoderma gangrenosum**
- following breast reconstructive surgery, case report on treatment with immunosuppression and adjunctive xenogeneic matrix scaffolds (RR), 545
- treatment with topical crushed dapsone (CR), 1059
- Q**
- Q-switched laser treatment**
- of amiodarone pigmentation (CR), 1316
- treating lentigenes in Asian patients with Q-switched Alexandrite laser (DP), s14 (December)
- QT intervals and QT dispersion**, isotretinoin does not prolong QT intervals and QT

dispersion in severe acne: a surprising finding for a drug with numerous side effects, 710

R

Race/ethnicity

- acne in patients with skin of color, s13 (June)
 advances in laser hair removal in skin of color, 1235
 advances in treatment of keloids, 468
 best practices and evidence-based use of 800 nm diode laser for pseudofolliculitis barbae in skin of color (DP), s20 (December)
 clinical pearls for dermal filler enhancement in patients with skin of color (DP), s23 (December)
 community-based study of skin conditions and concerns in South Asian Americans (BC), 524
 cosmetic treatments on skin of color, a unique challenge (editorial), s4 (December)
 dermal fillers in skin of color, 494
 diode 810 nm laser as safe, effective modality to meet a growing population need (DP), s8 (December)
 effectiveness of topical tacrolimus for vitiligo in skin of color, 507
 efficacy and safety of azelaic acid gel 15% in post-inflammatory hyperpigmentation and acne, 586
 fractional laser resurfacing for acne scarring in Fitzpatrick skin types IV–VI (DP), s6 (December)
 laser hair removal in ethnic skin, principles and practical aspects of (DP), s17 (December)
 laser hair removal pearls in skin of color (DP), s12 (December)
 melasma in Latin Americans, 517
 novel 0.65 millisecond pulsed 1064 nm laser to treat skin of color without skin cooling or anesthetics (DP), s10 (December)
 progressive macular hypomelanosis, 502
 retrospective study of racial and ethnic variations in psoriasis treatment with etanercept, 866
 safety and efficacy of cosmetic laser treatments for skin of color, 35
 scalp hyperkeratosis and alopecia in children of color, 511
 strategies minimizing irritation and iatrogenic post-inflammatory pigmentation in treating acne patients with skin of color (DP), s25 (December)
 ten tips for acne vulgaris treatment in Fitzpatrick skin types IV–VI (BC), 654
 topical retinoids for pigmented skin, 483
 treating lentigines in Asian patients with Q-switched Alexandrite laser (DP), s14 (December)
- Radiation therapy**
 electronic brachytherapy for non-melanoma skin cancer treatment (CTR), 206
 phase 2 trial of erlotinib prior to surgery or radiation in squamous cell cancer (CTR), 207
 study of total skin electron beam therapy in stage IB–IIIA mycosis fungoides (CTR), 209
- Radiofrequency device**, multiple facial burns with new Thermage CPT system (CR), 1320
- Radioiodine ablation of thyroid**, iododerma

following (RR), 1070

Rapamycin, recent advances and future directions in medical management of skin disease, 28

RAW 264.7 cells, taurine chloramine inhibits NO and TNF- α production in zymosan plus interferon- γ activated RAW 264.7 cells, 659

Reactive oxygen species

- assessment of kinetics of antioxidative capacity of topical antioxidants, 262
 complementary antioxidant function of caffeine and green tea polyphenols in normal human skin fibroblasts, 753
 green tea extract protects human skin fibroblasts from reactive oxygen species induced necrosis, 1096

Reconstructive surgery

- case report of pyoderma gangrenosum following breast reconstructive surgery treated with immunosuppression and adjunctive xenogeneic matrix scaffolds (RR), 545
 modified Tripiier flap for lateral eyelid reconstruction (CR), 199

Red light source, safety and efficacy comparison of blue versus red light sources for MAL-PDT in photodamaged skin, 53

Reflectance confocal microscopy (RCM), pilot study using RCM in assessment of novel formulation for melasma, 1260

REGN668, sequential ascending dose study on safety and tolerability in atopic dermatitis (CTR), 314

Renal conditions. See Kidneys

Resident Rounds (RR)

- Albert Einstein College of Medicine Unified Division of Dermatology Residency Program program spotlight, 1122
 autoimmune-mediated blisters (for the Boards), 491
 case of trichomycosis axillaris and erythrasma, 1472
 case report on pyoderma gangrenosum following breast reconstructive surgery treated with immunosuppression and adjunctive xenogeneic matrix scaffolds, 545
 cutaneous hypersensitivity during selective serotonin reuptake inhibitor therapy resulting in acquired cutis laxa, 215
 dermal melanoma in transplant patient, 808
 Eastern Virginia Medical School Dermatology Residency Program program spotlight, 344
 erosive and desquamative syphilis associated with mucositis in setting of AIDS, 1335
 eruptive plexiform schwannomas in child with neurofibromatosis I, 1210
 fulminant dermatomyositis with flagellate erythema, 902
 hair findings board review, 1464
 Harvard Combined Dermatology Residency Training Program program spotlight, 186
 high-yield dermatologic signs in Harvard Combined Residency Training Program, 197
 highlights of common autoimmune connective tissue diseases, 1314
 integrated basic and clinical sciences

conference, 1045

- intralymphatic histiocytosis associated with orthopedic implants, 1208
 iododerma following radioactive iodine ablation of thyroid for Graves disease, 1070
 levamisole-induced retiform purpura, 217
 nephrogenic systemic fibrosis: case report and literature review, 622
 nodoulcerative disease that still lingers after all these centuries, 1072
 Nova Southeastern University College of Osteopathic Medicine and Broward General Medical Center Dermatology Residency Training Program program spotlight, 467
 pediatric vascular anomalies, 893
 photomedicine board review facts, 750
 phototherapy-induced purpura in transient porphyria of neonate, 306
 reported adverse effects of isotretinoin and systemic corticosteroids, 287
 sound-alike and look-alike terms in dermatology, 1196
 study aid: diagnosis and associations, 611
 ticks of dermatologic significance, 365
 University of California Davis Department of Dermatology Residency Training Program program spotlight, 253
 University of California Irvine Department of Dermatology Residency Training Program program spotlight, 593
 University of California San Francisco Department of Dermatology Residency Training Program program spotlight, 883
 University of Connecticut Dermatology Residency program spotlight, 1452
 University of Louisville Dermatology Residency Training Program program spotlight, 1289
 University of Massachusetts Medical School Dermatology Residency Program program spotlight, 716
 University of Texas Southwestern Medical Center Dermatology Residency Program program spotlight, 1016
 viral-associated trichodysplasia of immunosuppression in renal transplant patient, 422
- Resident Spotlight (RS)**
 comparison of diagnostic and biopsy/referral sensitivity to melanoma between dermatologists and MelaFind, 1078
 winning poster: phase 2 open-label investigator-initiated study of safety and efficacy of apremilast in recalcitrant contact or atopic dermatitis, 928
 winning poster: predictive factors for severity of scar formation after skin cancer surgeries, 810
- Resveratrol-containing gel for acne (PP)**, 434
- Retinoids**
 adapalene gel 0.3% in atrophic acne scars (CTR), 96
 assessment of national trends in acitretin treatment of psoriasis, 873
 in combination treatment for moderate-to-severe acne (CTR), 90
 comparison of 1% tretinoin peeling versus 70% glycolic acid peeling in female patients with melasma, 1439
 comparison of retinol 1.0% and tretinoin

- 0.02% in moderate-to-severe photodamage and wrinkles (CTR), 1217
- decrease of insulin growth factor-1 as novel mechanism for anti-androgen effect of isotretinoin and its association with depression (BC), 793
- and depression, 409
- effect of retinoid pretreatment on outcomes of photodynamic therapy for actinic keratosis of hand and forearm, 1124
- Epiduo pediatric acne study (CTR), 90, 312
- isotretinoin does not prolong QT intervals and QT dispersion in severe acne: a surprising finding for a drug with numerous side effects, 710
- literature review on acitretin in dermatology, 772
- randomized study of dapsone gel 5% in combination with tazarotene cream 0.1% in acne vulgaris, 783
- reported adverse effects of systemic corticosteroids and isotretinoin (RR), 287
- rethinking treatment of acne in severe patient, s8 (June)
- review of chemopreventative effects for internal neoplasms, 1292
- safety and efficacy of micronized tretinoin 0.05% gel in adolescent acne, 647
- study comparing Aczone plus Differin to Duac plus Differin in severe facial acne (CTR), 312
- topical, for pigmented skin, 483
- in topical fixed-combination therapy and topical monotherapy in acne, evidence-based review on, 636
- Retinol**, comparison of retinol 1.0% and tretinoin 0.02% in moderate-to-severe photodamage and wrinkles (CTR), 1217
- Retinopathy**, central serous chorioretinopathy associated with topical corticosteroids in psoriasis (CR), 918
- Rheological evaluation** of physical properties of hyaluronic acid dermal fillers, 974
- commentary on (letter to the editor), 964
- Rhytids (rhytides)**. See Wrinkles
- Rituximab**
- dosing in refractory pemphigus vulgaris in adolescent male (CR), 202
- FDA approval of Rituxan with corticosteroids for severe vasculitis (PP), 683
- RNA**, small interfering, in pachyonychia congenita, 28
- Rosacea**
- inflammation in rosacea and acne, implications for patient care, 614
- investigator-blind randomized parallel-group study on efficacy of novel rosacea treatment system, 1179
- open label pilot study of Apremilast in (CTR), 313
- papulopustular, self-reported treatment impressions and satisfaction of patients treated with doxycycline USP 40 mg capsules for, 1376
- phase 3 efficacy and study of CD07805/47 topical gel in facial erythema associated with rosacea (CTR), 1216
- vehicle formulations affecting efficacy, tolerability, and compliance with topical therapy, 627
- Rose bengal**, randomized study of PH-10 for psoriasis (CTR), 315
- RT001**, topical neurotoxin erases crow's feet (PP), 1341
- Rupatadine** and levocetirizine in chronic idiopathic urticaria, comparative study of efficacy and safety, 1444
- S**
- Safe Cosmetics Act** of 2011 (PP), 1215
- Safety issues**
- in blue versus red light sources for MAL-PDT in photodamaged skin, 53
- in calcium hydroxylapatite rejuvenation of aging hand, 52-week study of, 47
- clinical evaluation of safety and efficacy of new topical treatment for onychomycosis, 1186
- clinical trial safety and mortality analysis of etanercept across approved indications, 289
- comparative study of efficacy and safety of rupatadine and levocetirizine in chronic idiopathic urticaria, 1444
- comparative study of safety and efficacy of 75% mulberry extract oil versus placebo as topical treatment for melasma, 1025
- in comparison of cryotherapy and imiquimod for actinic keratoses, 1432
- in cosmetic laser treatments for skin of color, 35
- in dermal fillers in skin of color population, 494
- diffuse large B-cell lymphoma associated with biologic and other investigational agents in psoriasis (CR), 80
- diode 810 nm laser as safe, effective modality to meet a growing population need (DP), s8 (December)
- dose-ranging study on safety and efficacy of IDP-107 in acne vulgaris (CTR), 426
- double-blind randomized vehicle-controlled study on efficacy and safety of naftifine 2% cream in tinea cruris, 1142
- double-blind randomized vehicle-controlled study on efficacy and safety of naftifine 2% cream in tinea pedis, 1282
- efficacy, safety, and tolerability of SRD174 cream for pruritus in atopic dermatitis, 853
- efficacy and safety of different concentrations of ZK245186 in atopic dermatitis (CTR), 313
- hair regrowth following a Wnt- and follistatin-containing treatment, safety and efficacy in first-in-man phase 1 clinical trials, 1308
- isotretinoin does not prolong QT intervals and QT dispersion in severe acne: a surprising finding for a drug with numerous side effects, 710
- in LEO 80185 topical suspension for adolescents with scalp psoriasis (CTR), 95
- long-term study to evaluate safety and tolerability of CP-690,550 in moderate-to-severe chronic plaque psoriasis (CTR), 94
- multi-center open-label study on safety and efficacy of sequential treatment regimen of clobetasol propionate spray followed by calcitriol ointment in plaque psoriasis, 158
- one-year study on efficacy and safety of CP-690,550 for moderate-to-severe chronic plaque psoriasis (CTR), 688
- open-label pilot study on effectiveness and safety of hyaluronic acid in lip augmentation, 145
- open-label prospective cohort pilot study on efficacy and safety of etanercept in moderate to severe plaque psoriasis in patients without adequate response to adalimumab, 396
- open-label study of safety and efficacy of sertaconazole nitrate in seborrheic dermatitis, 895
- phase 3 efficacy and study of CD07805/47 topical gel in facial erythema associated with rosacea (CTR), 1216
- phase 2 open-label investigator-initiated study of safety and efficacy of apremilast in recalcitrant contact or atopic dermatitis (RS), 928
- safety and effectiveness of small and large gel-particle hyaluronic acid in correction of perioral wrinkles, 982
- safety and efficacy of clindamycin phosphate 1.2%–benzoyl peroxide 3% fixed-dose combination gel for acne vulgaris, 1382
- safety and efficacy of clobetasol propionate 0.05% emollient foam in alopecia (CTR), 1077
- safety and efficacy of micronized tretinoin 0.05% gel in adolescent acne, 647
- safety and efficacy of secukinumab compared to etanercept in moderate-to-severe chronic plaque-type psoriasis (CTR), 1216
- safety and efficacy study of bimatoprost in women with female pattern hair loss (CTR), 936
- safety of tumescence and laser-assisted liposuction, review of literature on, 1363
- safety study of AMG 157 in healthy subjects and subjects with atopic dermatitis (CTR), 313, 687
- sequential ascending dose study on safety and tolerability of REGN668 in atopic dermatitis (CTR), 314
- study on clinical activity, safety, and tolerability of SRT2104 in moderate-to-severe plaque-type psoriasis (CTR), 92, 314
- study on efficacy and safety of GDC-0449 in operable basal cell carcinoma (CTR), 206
- study to evaluate safety and effectiveness of oral apremilast (CC-10004) in moderate-to-severe plaque psoriasis (CTR), 1487
- study to explore efficacy and safety of ASP015K in moderate-to-severe psoriasis (CTR), 93, 315
- Salicylic acid**
- in ammonium lactate emollient foam vehicle for scalp psoriasis, 270
- in Gly-Sal Acne Body Spray (PP), 434
- Salmeterol xinafoate**, injection lipolysis of abdominal subcutaneous fat yields results (PP), 103
- Sarcoma**, AIDS and HIV-related Kaposi sarcoma lenalidomide in (CTR), 210
- liposomal daunorubicin in (CTR), 212
- PTC299 in (CTR), 211

- Scalp cooling** in prevention of chemotherapy-induced alopecia (CTR), 936
- Scalp lesions**
- long-term complete sustained clearance of actinic keratoses of face or balding scalp after imiquimod treatment, 95
 - randomized controlled trial on clobetasol propionate 0.05% spray for moderate-to-severe plaque psoriasis of scalp, 885
 - safety and efficacy of LEO 80185 topical suspension in adolescents with scalp psoriasis (CTR), 95
 - salicylic acid 6% in ammonium lactate emollient foam vehicle for scalp psoriasis, 270
 - scalp hyperkeratosis and alopecia in children of color, 511
- Scars/scarring**
- adapalene gel in treatment of atrophic acne scars (CTR), 96
 - burn scar appearance after fractional carbon dioxide laser treatment (CTR), 96
 - effects of pulsed-dyed laser on scar formation (CTR), 96
 - evaluation of clinical improvement in acne scars and active acne in 1540-nm non-ablative fractional laser treatment, 907
 - fractional laser resurfacing for acne scarring in Fitzpatrick skin types IV–VI (DP), s6 (December)
 - multi-center clinical study and review of fractional ablative carbon dioxide laser resurfacing for rhytides, photoaging, scars, and striae, 352
 - treatment of surgical scars using pulsed dye laser (CTR), 96, 1216
 - winning poster: predictive factors for severity of scar formation after skin cancer surgeries (RS), 810
- Schwannoma**, eruptive plexiform, in child with neurofibromatosis I (RR), 1210
- Screening**, early detection and cure of melanoma in serial screening, 244
- Seborrheic dermatitis**, open-label study of safety and efficacy of sertaconazole nitrate in, 895
- Secukinumab**, safety and efficacy of secukinumab compared to etanercept in moderate-to-severe chronic plaque-type psoriasis (CTR), 1216
- Serotonin reuptake inhibitor therapy, selective**, cutaneous hypersensitivity to resulting in acquired cutis laxa (RR), 215
- Sertaconazole nitrate**
- open-label study of safety and efficacy in seborrheic dermatitis, 895
 - treatment of interdigital tinea pedis with once-daily therapy with, 1135
- Sézary syndrome**. *See* Mycosis fungoides/Sézary syndrome
- Skin barrier function**
- clinical relevance of maintaining structural and functional integrity of stratum corneum, s5 (October)
 - comparison of OTC moisturizer and prescription barrier creams in mild-to-moderate atopic dermatitis of children, 531
 - effects of novel flucinonide cream formulation on, in atopic dermatitis, 171
 - managing epidermal barrier function in treatment of dermatoses, s13 (October)
- new body moisturizer increases skin hydration and improves atopic dermatitis symptoms in children and adults, 744
- role of stratum corneum in healthy and diseased skin (editorial), s4 (October)
- Topix Pharmaceuticals, Inc. releases Replenix ResurFIX Skin Barrier Healing Ointment (PP), 805
- Skin cancer**
- cancer: this war is personal (editorial), 237
 - clinical trial of Dermacorder for detecting malignant skin lesions (CTR), 317
 - comparison of diagnostic and biopsy/referral sensitivity to melanoma between dermatologists and MelaFind (RS), 1078
 - comparison of elective lymph node treatment versus clinical observation in absence of palpable lymph nodes in high risk squamous cell carcinoma (CTR), 207
 - confocal microscopy of cutaneous neoplasms and normal skin (CTR), 318
 - dasatinib in locally advanced or metastatic mucosal melanoma, acral melanoma, or solar melanoma that cannot be removed by surgery (CTR), 208
 - dasatinib in unresectable or metastatic squamous cell skin cancer or RAI stage 0-1 chronic lymphocytic leukemia (CTR), 207
 - dermal melanoma in renal transplant patient (RR), 808
 - early detection and cure in serial screening for melanoma, 244
 - electronic brachytherapy for non-melanoma skin cancer treatment (CTR), 206
 - eruptive squamous cell carcinoma with keratoacanthoma-like features in sorafenib treatment (CR), 308
 - FDA gives provisional approval to MelaFind device (PP), 1340
 - FDA panel votes in favor of MelaFind skin cancer detection device (PP), 213
 - imatinib in mucosal or acral/lentiginous melanoma (CTR), 208
 - lessons from an exemplary physician in private setting (editorial), 238
 - Merkel cell carcinoma as banal-appearing aggressive actor (NVR), 811
 - Mohs micrographic surgery for cutaneous lymphadenoma (CR), 1324
 - new drug applications for vemurafenib in advanced skin cancer (PP), 805
 - novel devices for diagnosis and treatment, 21
 - phase 2 trial of erlotinib prior to surgery or radiation in (CTR), 207
 - sorafenib and temsirolimus in metastatic, recurrent, or unresectable melanoma (CTR), 207
 - spectral diagnosis of cutaneous malignancy (CTR), 318
 - study confirms sunscreen prevents melanoma (PP), 213
 - study of ultrasonography with elastography in skin neoplasms (CTR), 319
 - study on efficacy and safety of GDC-0449 in operable basal cell carcinoma (CTR), 206
 - three-dimensional Mohs surgery, a new concept, 1273
 - trends in treatment and detection of, 16
 - triage in Mohs micrographic surgery, 257
 - ulcerated nodular nasal basal cell carcinoma successfully treated with imiquimod 5% cream (letter to the editor), 240
 - unresectable or metastatic, dasatinib in (CTR), 207
 - use of gelatin sponges in Mohs micrographic surgery and staged melanoma excision, 68
 - winning poster: predictive factors for severity of scar formation after skin cancer surgeries (RS), 810
- Skin Health Experimental Product (SHEP)**, phase 2 double-blind randomized placebo-controlled trial of novel nutritional supplement product to promote healthy skin, 1106
- Skin lightening products**
- FDA ban on skin whitening products containing mercury (PP), 1215
 - natural therapies for hyperpigmentation, s11 (September), s15 (September)
- Skin of color**
- acne in patients with, s13 (June)
 - advances in laser hair removal in, 1235
 - advances in treatment of keloids, 468
 - best practices and evidence-based use of 800 nm diode laser for pseudofolliculitis barbae in skin of color (DP), s20 (December)
 - clinical pearls for dermal filler enhancement in patients with skin of color (DP), s23 (December)
 - community-based study of skin conditions and concerns in South Asian Americans (BC), 524
 - cosmetic treatments on skin of color, a unique challenge (editorial), s4 (December)
 - dermal fillers in, 494
 - diode 810 nm laser as safe, effective modality to meet a growing population need (DP), s8 (December)
 - effectiveness of topical tacrolimus for vitiligo in, 507
 - efficacy and safety of azelaic acid gel 15% in post-inflammatory hyperpigmentation and acne, 586
 - fractional laser resurfacing for acne scarring in Fitzpatrick skin types IV–VI (DP), s6 (December)
 - laser hair removal in ethnic skin, principles and practical aspects of (DP), s17 (December)
 - laser hair removal pearls in skin of color (DP), s12 (December)
 - melasma in Latin Americans, 517
 - novel 0.65 millisecond pulsed 1064 nm laser to treat skin of color without skin cooling or anesthetics (DP), s10 (December)
 - progress made, challenges remain (editorial), 459
 - progressive macular hypomelanosis, 502
 - retrospective study of racial and ethnic variations in psoriasis treatment with etanercept, 866
 - safety and efficacy of cosmetic laser treatments for, 35
 - scalp hyperkeratosis and alopecia in children of color, 511
 - strategies minimizing irritation and iatrogenic post-inflammatory pigmentation in treating acne patients with (DP), s25 (December)

- ten tips for acne vulgaris treatment in Fitzpatrick skin types IV–VI (BC), 654
- topical retinoids for pigmented skin, 483
- Skin resurfacing**
- EndyMed Medical receives FDA clearance for Fractional Skin Resurfacing Applicator (PP), 435
- nonablative 1927 nm fractional resurfacing for actinic keratoses (PP), 103
- safety and efficacy of cosmetic laser treatments for skin of color, 37
- Sodium sulfacetamide-sulfur** in topical rosacea therapy, vehicle formulations for, 627
- Sodium thiosulfate**, topical sodium thiosulfate 25% treatment for ulcerative calcinosis cutis, 1042
- Soft tissue augmentation**
- combined treatment for skin rejuvenation and soft-tissue augmentation of aging face, 125
- management of impending necrosis associated with soft tissue filler injections (CR), 1007
- Sorafenib**
- chloracne-like drug eruption associated with (CR), 1331
- eruptive squamous cell carcinomas with keratoacanthoma-like features in patients treated with (CR), 308
- erythema multiforme-like drug reaction to (CR), 1462
- and temsirolimus in metastatic, recurrent, or unresectable melanoma (CTR), 207
- Sound-line and look-alike terms** in dermatology (RR), 1196
- South Asian Americans**, community-based study of skin conditions and concerns in (BC), 524
- Soy products**
- aesthetic benefits of natural ingredients in skin care, s11 (September)
- for hyperpigmentation, s16 (September)
- Spectral diagnosis** of cutaneous malignancy (CTR), 318
- Spinosad**, FDA approves Natroba for head lice (PP), 434
- Spironolactone**
- advantages of oral contraceptives and spironolactone for women with acne (DP), 941
- in female androgenetic alopecia (NVR), 100
- Squamous cell carcinoma (SCC)**
- comparison of elective lymph node treatment versus clinical observation in absence of palpable lymph nodes in high risk SCC (CTR), 207
- dasatinib in unresectable or metastatic squamous cell skin cancer or RAI stage 0-1 chronic lymphocytic leukemia (CTR), 207
- electronic brachytherapy for treatment of (CTR), 206
- eruptive, with keratoacanthoma-like features in sorafenib treatment (CR), 308
- phase 2 trial of erlotinib prior to surgery or radiation in (CTR), 207
- SRD174 cream**, efficacy, safety, and tolerability of SRD174 cream for pruritus in atopic dermatitis, 853
- SRT2104**, study of clinical activity, safety, and tolerability in moderate-to-severe plaque-type psoriasis (CTR), 92, 314
- Staphylococcus aureus**, FDA approves Ceftaroline for MRSA (PP), 104
- START** (Swiss Taxotere Alopecia Prevention Trial) (CTR), 936
- Stevens-Johnson syndrome**, short-term and low-dose oral fluconazole treatment can cause Stevens-Johnson syndrome in HIV-negative patients (letter to the editor), 1360
- Stoma site**, treatment of peristomal pyoderma gangrenosum with topical crushed dapsone (CR), 1059
- Stomach cancer**, clinical clues and patterns in biopsy diagnosis of cutaneous metastases (NVR), 678, 930
- Stratum corneum**
- clinical relevance of maintaining structural and functional integrity of, s5 (October)
- managing epidermal barrier function in treatment of dermatoses, s13 (October)
- role in healthy and diseased skin (editorial), s4 (October)
- Striae**, multi-center clinical study and review of fractional ablative carbon dioxide laser resurfacing for rhytides, photoaging, scars, and striae, 352
- Strongyloidiasis**, fatal cutaneous, as side effect of mycophenolate mofetil in pemphigus foliaceus (CR), 418
- Sunscreens**
- Cleure launches FDA-approved broad-spectrum sunscreen (PP), 1076
- impact of natural sunlight exposure on UVB-SPF and UVA-PF of UVA/UVB SPF 50 sunscreen, 150
- in novel rosacea treatment system, investigator-blind randomized parallel-group study on, 1179
- study confirms sunscreen prevents melanoma (PP), 213
- Swiss Taxotere Alopecia Prevention Trial** (START) (CTR), 936
- Syphilis**
- erosive and desquamative, associated with mucositis in setting of AIDS (RR), 1335
- and lues maligna in HIV infection (RR), 1072
- T**
- T cell(s)**
- CD70 and Th17 involvement in human contact sensitivity (BC), 1192
- repertoire analysis of immune mediated skin diseases (CTR), 936
- T cell leukemia/lymphoma, adult (ATLL)**, vesiculobullous variant in Caribbean émigré (CR), 1469
- T cell lymphoma**
- Pralatrexate in Patients with Relapsed or Refractory Peripheral T-Cell Lymphoma (PROPEL) (PP), 213
- review of chemopreventative effects of oral retinoids for cutaneous T cell lymphoma, 1292
- study evaluating two dose levels of Targretin capsules in refractory cutaneous T cell lymphoma (CTR), 209
- Tacrolimus**, topical, effectiveness for vitiligo in skin of color, 507
- Tamoxifen**-induced hirsutism (CR), 799
- Tattoos**
- malignancy arising within, case of dermatofibrosarcoma protuberans and review of literature, 837
- and psoriasis (CR), 1199
- topical imiquimod with Nd:YAG laser for removal of (CTR), 1342
- Taurine chloramine** inhibits NO and TNF- α production in zymosan plus interferon- γ activated RAW 264.7 cells, 659
- Tazarotene**
- effect of retinoid pretreatment on outcomes of photodynamic therapy for actinic keratosis of hand and forearm, 1124
- randomized study of dapsone gel 5% in combination with tazarotene cream 0.1% in acne vulgaris, 783
- in topical monotherapy for acne, compared to fixed-combination therapy, 636
- Temporal fossa augmentation** with small gel particle hyaluronic acid dermal filler, 673
- Temsirolimus** and sorafenib in metastatic, recurrent, or unresectable melanoma (CTR), 207
- Tetanus, diphtheria and pertussis vaccination**, case of lichen planus following (CR), 1067
- Tetrahydroxypropyl ethylenediamine (THPE)**, clinical evidence for activity of THPE as new anti-aging active cosmetic, 1102
- Thalidomide**, and complement activation by *Mycobacterium leprae*, 274
- Thermage CPT system**, multiple facial burns with (CR), 1320
- Thrombocytopenia** in tumor necrosis factor- α inhibitor therapy for psoriasis, frequency of, 280
- Thyroid**
- clinical clues and patterns in biopsy diagnosis of cutaneous metastases of thyroid cancer (NVR), 678, 930
- iododerma following radioactive iodine ablation of thyroid for Graves disease (RR), 1070
- Ticks** of dermatologic significance (RR), 365
- Tinea cruris**, double-blind randomized vehicle-controlled study on efficacy and safety of naftifine 2% cream in, 1142
- Tinea pedis**
- once-daily therapy with sertaconazole nitrate for, 1135
- randomized double-blind vehicle-controlled efficacy and safety study of naftifine 2% cream in, 1282
- Total skin electron beam therapy (TSEBT)** in stage IB-IIIa mycosis fungoides (CTR), 209
- Tower technique** for injection of hyaluronic acid fillers, 1277
- Training**
- Albert Einstein College of Medicine Unified Division of Dermatology Residency Program (RR), 1122, 1196, 1208
- autoimmune-mediated blisters (for the Boards) (RR), 491
- CME: demystifying acne algorithms, s5 (June), s24 (June), s26 (June)
- CME: identifying natural ingredients and their use in skin care, s4 (September), s21 (September), s22 (September)
- Eastern Virginia Medical School Dermatology Residency Program (RR), 344, 365, 422
- hair findings board review (RR), 1464
- Harvard Combined Dermatology Residency Training Program (RR), 186, 197
- high yield dermatologic signs (RR), 197
- highlights of common autoimmune

- connective tissue diseases (RR), 1314
- integrated basic and clinical sciences conference (RR), 1045
- nanotechnology and dermatology education in United States, data from pilot survey, 1037
- Nova Southeastern University College of Osteopathic Medicine and Broward General Medical Center Dermatology Residency Training Program (RR), 467, 491, 545
- pediatric vascular anomalies (RR), 893
- photomedicine board review facts (RR), 750
- sound-alike and look-alike terms in dermatology (RR), 1196
- study aid: diagnosis and associations (RR), 611
- University of California Davis Department of Dermatology Residency Training Program (RR), 253, 287, 306
- University of California Irvine Department of Dermatology Residency Training Program (RR), 593, 611, 622
- University of California San Francisco Department of Dermatology Residency Training Program (RR), 883, 893, 902
- University of Connecticut School of Medicine Dermatology Residency (RR), 1452, 1464, 1472
- University of Louisville School of Medicine Dermatology Residency Training Program (RR), 1289, 1314, 1335
- University of Massachusetts Medical School Dermatology Residency Program (RR), 716, 750, 808
- University of Texas Southwestern Medical Center Dermatology Residency Program (RR), 1016, 1045, 1070, 1072
- Transepidermal water loss**
- effects of novel fluocinonide cream formulation on skin barrier function in atopic dermatitis, 171
- new body moisturizer increases skin hydration and improves atopic dermatitis symptoms in children and adults, 744
- Transplant recipients**
- melanoma in renal transplant patient (RR), 808
- viral-associated trichodysplasia of immunosuppression in renal transplant patient (RR), 422
- Tretinoin**
- in combination treatment for moderate-to-severe acne (CTR), 90
- comparison of 1% tretinoin peeling versus 70% glycolic acid peeling in female patients with melasma, 1439
- comparison of retinol 1.0% and tretinoin 0.02% in moderate-to-severe photodamage and wrinkles (CTR), 1217
- safety and efficacy of micronized tretinoin 0.05% gel in adolescent acne, 647
- in topical monotherapy for acne, compared to fixed-combination therapy, 636
- Triage** in Mohs micrographic surgery, 257
- Trichodysplasia of immunosuppression**, viral-associated, in renal transplant patient (RR), 422
- Trichomycosis axillaris**, and erythrasma, case of (RR), 1472
- Tripier flap**, modified, for lateral eyelid reconstruction (CR), 199
- Triple compression bandage** and chitosan gel in treatment of venous leg ulcers, 75
- Tumeric**, aesthetic benefits of natural ingredients in skin care, s12 (September)
- Tumescent liposuction**, safety of tumescent and laser-assisted liposuction, review of literature on, 1363
- Tumor necrosis factor- α**
- adalimumab plus narrowband ultraviolet B light phototherapy for moderate to severe psoriasis, 366
- clinical trial safety and mortality analysis in patients receiving etanercept across approved indications, 289
- etanercept as sole treatment for grade I acute graft versus host disease (CTR), 1487
- frequency of thrombocytopenia in psoriasis treated with tumor necrosis factor- α inhibitors, 280
- Mycobacterium fortuitum* infection following adalimumab treatment for psoriasis and subsequent complication-free treatment with alternate TNF- α blockers (CR), 914
- open-label prospective cohort pilot study on efficacy and safety of etanercept in moderate to severe plaque psoriasis in patients without adequate response to adalimumab, 396
- retrospective study of racial and ethnic variations in psoriasis treatment with etanercept, 866
- review of infliximab treatment for psoriasis in 120 patients on therapy for a minimum of one year, 539
- safety and efficacy of secukinumab compared to etanercept in moderate-to-severe chronic plaque-type psoriasis (CTR), 1216
- taurine chloramine inhibits NO and TNF- α production in zymosan plus interferon- γ activated RAW 264.7 cells, 659
- topical calcipotriene 0.005% and betamethasone dipropionate 0.064% maintains efficacy of etanercept after step-down dose in moderate-to-severe plaque psoriasis, 878
- treatment of recalcitrant generalized granuloma annulare with adalimumab (CR), 1466
- Tyrosinase**, aesthetic benefits of natural ingredients in skin care, s11 (September)
- Tyrosinase inhibitors**, aesthetic benefits of natural ingredients in skin care, s11 (September)
- U**
- Ulcers**
- dermaPACE device for diabetic foot ulcers (PP), 325
- novel treatment for ulcerative calcinosis cutis, 1042
- pain management in debridement of leg ulcers (PP), 324
- Topix Pharmaceuticals releases Replenix ResurFIX Skin Barrier Healing Ointment (PP), 805
- treatment efficacy of triple bandage compression and chitosan gel in venous leg ulcers, 75
- ulcerated nodular nasal basal cell carcinoma successfully treated with imiquimod 5% cream (letter to the editor), 240
- Ultrasonography** with elastography in skin neoplasms (CTR), 319
- Ultraviolet (UV) radiation exposure**
- adalimumab plus narrowband UV B light phototherapy for moderate to severe psoriasis, 366
- assessment of antioxidative capacity kinetics of topical antioxidants in, 262
- Cleure launches FDA-approved broad-spectrum sunscreen (PP), 1076
- complementary antioxidant function of caffeine and green tea polyphenols in normal human skin fibroblasts, 753
- evaluation of prescription strength 4% hydroquinone/10% L-ascorbic acid treatment system for photodamage in normal to oily skin, 1455
- impact on UVB-SPF and UVA-PF of UVA/UVB SPF 50 sunscreen, 150
- in keloids (NVR), 550
- multiplexed 1,440 and 1,320 nm fractionated laser for chronic photodamage, 1266
- Unified Division of Dermatology of Albert Einstein College of Medicine**
- eruptive plexiform schwannomas in child with neurofibromatosis I (RR), 1210
- intralymphatic histiocytosis associated with orthopedic implants (RR), 1208
- program spotlight on Residency Program (RR), 1122
- sound-alike and look-alike terms in dermatology (RR), 1196
- University of California-Davis**
- phototherapy-induced purpura in transient porphyria of neonate (RR), 306
- program spotlight on Department of Dermatology Residency Training Program (RR), 253
- reported adverse effects of isotretinoin and systemic corticosteroids (RR), 287
- University of California-Irvine**
- nephrogenic systemic fibrosis: case report and literature review (RR), 622
- program spotlight on Dermatology Residency Training Program (RR), 593
- study aid: diagnosis and associations (RR), 611
- University of California-San Francisco**
- fulminant dermatomyositis with flagellate erythema (RR), 902
- pediatric vascular anomalies (RR), 893
- program spotlight on Department of Dermatology Residency Training Program (RR), 883
- University of Connecticut School of Medicine**
- case of trichomycosis axillaris and erythrasma (RR), 1472
- hair findings board review (RR), 1464
- program spotlight on Dermatology Residency (RR), 1452
- University of Louisville School of Medicine**
- erosive and desquamative syphilis associated with mucositis in setting of AIDS (RR), 1335
- highlights of common autoimmune connective tissue diseases (RR), 1314
- program spotlight on Dermatology Residency

Training Program (RR), 1289

University of Massachusetts Medical School
dermal melanoma in transplant patient (RR), 808
photomedicine board review facts (RR), 750
program spotlight on Dermatology Residency Program (RR), 716

University of Texas Southwestern Medical Center
integrated basic and clinical sciences conference (RR), 1045
iododerma following radioactive iodine ablation of thyroid for Graves disease (RR), 1070
noduloulcerative disease that still lingers after all these centuries (RR), 1072
program spotlight on Dermatology Residency Program (RR), 1016

Urticaria

chronic, treatment with colchicine, 1423
chronic idiopathic, comparative study of efficacy and safety of rupatadine and levocetirizine in, 1444
drug-induced, causes and clinical courses of, 1019

V**Vaccines**

bullous pemphigoid after herpes zoster vaccine administration (CR), 1328
case of lichen planus following Tdap vaccination (CR), 1067
FDA approves Gardasil to prevent anal cancer (PP), 325
herpes zoster vaccine reduces zoster risk (PP), 324

Vascular anomalies, pediatric (RR), 893

Vasculitis, FDA approval of Rituxan with corticosteroids for (PP), 683

VB-201, study to assess in psoriasis (CTR), 93, 316

Vehicle formulations

in topical acne therapy, importance of, s17 (June)
in topical rosacea therapy, affecting efficacy, tolerability, and compliance, 627

Vemurafenib

new drug applications for vemurafenib in advanced skin cancer (PP), 805
Zelboraf receives FDA approval (PP), 1215

Venous leg ulcers, treatment efficacy of triple bandage compression and chitosan gel in, 75

Vismodegib, Genentech submits New Drug Application to FDA (PP), 1340

Vitamin D

Abbott files for 510(k) clearance for vitamin D assay (PP), 684
in keloids (NVR), 550
multi-center open-label study on safety and efficacy of sequential treatment regimen of clobetasol propionate spray followed by calcitriol ointment in plaque psoriasis, 158

Vitiligo vulgaris

in skin of color, effectiveness of topical tacrolimus treatment in, 507
treatment with melanocyte-keratinocyte cell suspension versus dermabrasion only in pilot study with 12-month follow-up, 1032

Vorinostat, efficacy in combination with interferon alpha and extracorporeal photopheresis in late stage mycosis fungoides and Sézary syndrome (BC), 403

W**Warts**

comparison of dimethyl ether and propane to liquid nitrogen in cryosurgical treatment of, case report and review of literature on, 1174

FDA approves Zyclara Cream 3.75% for external genital warts (PP), 552

metabolic syndrome and surrogate markers of increased cardiovascular risk in children with moderate-to-severe psoriasis compared to age-matched population with warts (BC), 900

Wegener's granulomatosis, FDA approval of Rituxan with corticosteroids for (PP), 683

Wnt, hair regrowth following a Wnt- and follistatin-containing treatment, safety and efficacy in first-in-man phase 1 clinical trials, 1308

World Congress of Dermatology, Syneron devices introduced at (PP), 805

Wound healing

from basic science to clinical practice and beyond (NVR), 427

Cardium Therapeutics announces FDA 510(k) clearance for Excellagen (PP), 1478

case report of pyoderma gangrenosum following breast reconstructive surgery treated with immunosuppression and adjunctive xenogeneic matrix scaffolds (RR), 545

randomized double-blind petrolatum-controlled study on efficacy of oregano extract ointment in, 1168

secondary, in use of gelatin sponges in Mohs micrographic surgery defects and staged melanoma excisions, 68

Topix Pharmaceuticals releases Replenix ResurFIX Skin Barrier Healing Ointment (PP), 805

treatment efficacy of triple bandage compression and chitosan gel in venous leg ulcers, 75

winning poster: predictive factors for severity of scar formation after skin cancer surgeries (RS), 810

Wrinkles

azficel-T in nasolabial folds and wrinkles (PP), 325, 939

comparing clinical attributes of abobotulinumtoxinA and onabotulinumtoxinA using Frontalis Rating Scale and Frontalis Activity Measurement Standard, 1148

comparison of retinol 1.0% and tretinoin 0.02% in moderate-to-severe photodamage and wrinkles (CTR), 1217

corrugator supercillii muscle terminal nerve ablation using novel thread technique for treatment of hyperdynamic vertical glabellar furrows, 762

Crutchfield Dermatology now offers Selphyl wrinkle treatment (PP), 213

efficacy and tolerability of new monophasic double-crosslinked hyaluronic acid filler for deep lines and, 134

efficacy of cream-based novel formulations of hyaluronic acid of different molecular weights in anti-wrinkle treatment, 990

Ellman International introduces Pellevé Wrinkle Reduction System to European market (PP), 938

FDA approval for Syneron LED-based skin rejuvenation system (PP), 435

FDA approval of Xeomin (incobotulinumtoxinA) for glabellar lines (PP), 1076

histological and immunohistochemical evaluation of intense pulsed light photorejuvenation for, 1246

La Roche-Posay introduces new products (PP), 938

multi-center clinical study and review of fractional ablative carbon dioxide laser resurfacing for rhytides, photoaging, scars, and striae, 352

rapid onset of response and patient-reported outcomes after onabotulinumtoxinA treatment of moderate-to-severe glabellar lines, 39

safety and effectiveness of small and large gel-particle hyaluronic acid in correction of perioral wrinkles, 982

safety and efficacy of calcium hydroxylapatite for rejuvenation of aging hand, 47
solid hyaluronic acid tailored to fix fine wrinkles (PP), 1341

Taenda Luxe Device for home treatment of periorbital wrinkles (PP), 1215
topical neurotoxin erases crow's feet (PP), 1341

tower technique for injection of hyaluronic acid fillers in, 1277

WS-1 fibroblast cells, complementary antioxidant function of caffeine and green tea polyphenols in normal human skin fibroblasts, 753

Z

Zanolimumab, study of human monoclonal antibody to treat mycosis fungoides and Sézary syndrome (CTR), 1077

Zinc

and copper in natural therapies for hyperpigmentation, s18 (September)

randomized double-blind placebo-controlled multi-center trial of zinc for herpes simplex labialis, 1343

ZK245186 in atopic dermatitis, efficacy and safety of different concentrations (CTR), 313

Zoster, herpes zoster vaccine reduces zoster risk (PP), 324

Zyosan, taurine chloramine inhibits NO and TNF- α production in zyosan plus interferon- γ activated RAW 264.7 cells, 659